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Tryptophan 2,3-dioxygenase (TDO), along with indoleamine 2,3-dioxygenase (IDO) 
and indoleamine 2,3-dioxygenase-2 (IDO2) are the three enzymes that catalyse 
oxidation of L-tryptophan (L-Trp) in the first step of the kynurenine pathway. 
Despite the fact that all three catalyse the same reaction, they were detected and 
characterized in different chronological periods; TDO, IDO and IDO2 were 
discovered in 1936, 1967 and 2007 respectively. Years of studies showed that 
abnormal regulation of L-Trp, in the first step of kynurenine pathway, is related with 
several disorders, including cancer. Regardless of their distinct dissimilarities, TDO, 
IDO and IDO2 were all detected in various cancers, supporting tumour escape and 
survival. The early identification of IDO immunomodulatory action (1990s) led to 
intense research for the development of IDO inhibitors, but not TDO. Despite this 
effort, the most pharmacologically suitable IDO inhibitor, 1-methyltryptophan (1-
MT), appears to be ineffective as monotherapeutic drug. Discovery of IDO2 showed 
that 1-MT action is not fully understood, raising questions about the biological 
significance of IDO2. 
 The ultimate goal of the current study was to address the problems outlined 
above. Because TDO and IDO are two druggable molecular targets, the discovery of 
a new class of effective inhibitors was pursued. Plate screening of ~2800 potential 
inhibitor compounds obtained from National Cancer Institute (NCI), USA, indicated 
seven promising compounds that inhibit both TDO and IDO in either nanomolar or 
low micromolar range. Interestingly, of these seven inhibitors, six have been 
identified to have cytotoxic action against several types of tumour cell lines (NCI 
data). NSC 26326, known as β-lapachone, is a natural occurring quinone and the 
strongest inhibitor of all seven. This NCI compound inhibits both TDO and IDO with 
inhibition constants of ~30-70 nM and 97 ± 14 nM respectively. Like NSC 26326, 
NSC 36398 is another natural occurring product and the only compound that showed 
selectivity against TDO with inhibition constant of 16.3 ± 3.8 µM. Among the seven 
compounds that displayed promise as inhibitors of TDO and IDO was mitomycin C. 
Mitomycin C, which is an approved oncology drug and a known inhibitor of IDO  
 VI 
(Ki = 24.2 ± 1.2 µM), is also inhibitor of TDO with inhibition constant of 2.86 ± 0.03 
µM. Another major goal of the current work was the discovery of isatin derivatives 
as inhibitors of TDO and IDO. Using the tryptophan-like structure of isatin as 
starting point, a number of structural modifications were carried out (structure-
activity relationship (SAR)) succeeding the optimization of their inhibition activity. 
This new family of TDO and IDO inhibitors demonstrated inhibition potencies in the 
low micromolar range with 5,7-dicholoisatin to reach the nanomolar range (in the 
case of TDO).  Halogenation of isatin and its derivatives was found to increase 
noticeably the inhibition potencies of these molecules by 12fold and 6fold for TDO 
and IDO respectively while breakdown of isatin’s pyrrolidine ring had a disastrous 
result on the inhibition of both enzymes. Combinations of 1-MT with either the 
newly-identified NCI inhibitors or the isatin derivatives were also examined. The in 
vitro combinations of 1-MT with either the NCI inhibitors or the isatin derivatives 
revealed an additive effect without though excluding the possibility of synergistic 
effect in vivo. 
 The specificity of TDO, IDO and IDO2 against the two stereoisomers of 1-
MT was also investigated, with interesting results. While IDO is inhibited only by 
the L-isoform of 1-MT (Ki = 18.0 ± 3.4 µM), IDO2 is inhibited by both 1-Me-L-Trp 
and 1-Me-D-Trp with inhibition constants of 306 ± 17 µM and 3419 ± 259 µM 
respectively. Biochemical characterization of human IDO2 was another goal of the 
current thesis, which completed successfully. Kinetic, redox and inhibition study of 
human IDO2 indicated significant differences in comparison with human IDO 
something which suggests the potential implication of IDO2 in an identified 
biological pathway (other than tryptophan catabolism function).The findings 
presented herein help to solve the mystery of 1-MT action, at least in vitro, give 
answers in regards to IDO2 function, and provide a number of new, promising 
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1.1 Heme-dependent proteins 
 
 
Heme-dependent proteins are a family of metalloproteins that contain one or more 
heme groups, which may or may not be covalently bound to the polypeptide chain. 
The study of this family is estimated to have started in the 19th century, when 
hemoglobin from several animals was recognised and crystallised for the first time 
(1). Heme proteins are responsible for a number of functions including electron 
transfer (e.g. cytochrome c), catalysis (e.g. catalase), oxygen transport and storage 
(e.g. hemoglobin and myoglobin) and signal transduction (e.g. nitric oxide synthase). 
Regardless of the functional specificity of each one, heme-dependent proteins share 
the same chromophore; a porphyrin moiety with an iron atom at the centre. The 
porphyrin moiety may be derivatised in various ways, and thus hemes are classified 
into several categories, of which heme a, heme b, heme c and heme d are the most 




Figure 1.1: Chemical structures of the most common types of heme (taken from ref. 2) 
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Between the four, iron (II) protoporphyrin IX (heme b) is the most common one. It 
serves as the template from which the other three types (a, c and d) are 
biosynthetically derived (2). Incorporation of the iron atom into any type of 
porphyrins occurs in vivo via an enzyme called ferrochelatase (3). During that 
process, four of the six coordination positions of iron are utilized for binding with the 
4 nitrogen atoms of porphyrin while the other two remain free for interactions with 
the active site of the given protein and a ligand such as oxygen (O2), nitric oxide 
(NO) and carbon monoxide (CO). During the several functions of heme proteins, the 
iron atom can generally adopt two stable oxidation forms, the ferric (Fe+3) and the 
ferrous (Fe+2) form. In addition to these two oxidation stages, heme can also adopt 
the ferryl (Fe+4) form, transiently, as part of the enzyme’s catalytic circle. In 
cytochrome P450 (CYP 450) monooxygenases, heme iron-bound dioxygen is 
believed to form compound-I species (Fe4+=O2− with a π-cation radical on the 
porphyrin ring) while in dioxygenases (indoleamine 2,3-dioxygenase), it was shown 
that catalysis occurs via a compound-II species  (Fe4+=O2− without a π-cation radical 




At the beginning of the 1930s the scientific world believed that incorporation of 
molecular oxygen into a substrate was completely forbidden. According to Heinrich 
Wieland, a German Nobel Laureate in chemistry and the father of “dehydrogenation 
theory”, dioxygen could serve only as acceptor of electrons via several carriers (6). 
Oxygen atoms that were incorporated into a substrate were considered to be derived 
from the oxygen atoms of water molecules.  
 In 1955 Osamu Hayaishi from Japan and Howard S. Mason from the US, 
working independently, demonstrated for the first time that dioxygen has the ability 
to react directly with a target molecule. While Hayaishi demonstrated the 
incorporation of molecular oxygen into catechol to produce cis,cis-muconic acid (7) 
(fig. 1.2), Mason showed the oxidation of 3,4-dimethylphenol to 4,5–
dimethylcatechol using an oxygen atom from molecular oxygen (8).  Both of these 
reactions were catalysed by a new enzyme family, which we call today oxygenases. 
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Oxygenases are defined as the enzymes that catalyse the incorporation of one or both 
atoms of dioxygen into the substrate. According to the number of oxygen atoms that 






Figure 1.2:  The reaction catalysed by catechol 1,2-dioxygenase; the first 





Monooxygenases are responsible for the enzymatic integration of an oxygen atom of 
dioxygen into the substrate, with the second oxygen being reduced to water. Further 
classification of monooxygenases reveals two subcategories (9); the internal 
monooxygenases where all the electrons required for the reaction come from the 
substrate (e.g. Arginine 2-monooxygenase EC 1.13.12.1, see reaction I) and the 
external monooxygenases where the electrons are obtained from coenzymes such as 
NADPH and FAD (e.g. Flavin-containing monooxygenase EC 1.14.13.8, see 
reaction II).  Heme oxygenases (HOs), flavin-containing monooxygenase (FMO) 
protein family, and cytochromes P450 are the most well-known monooxygenases.   
  
L-Arginine + O2 → 4-guanidinobutanamide + CO2 + H2O  (I)                            
 
N,N-dimethylaniline + NADPH + O2 → N,N-dimethylaniline N-oxide + NADP




Dioxygenases catalyse reactions in which both atoms of molecular oxygen are 
inserted into the substrate(s). Dioxygenases can be categorized into three groups (9). 
When both oxygen atoms from the molecular oxygen are fused into the same 
substrate then this class of dioxygenases is known as intramolecular dioxygenases 
(e.g. tryptophan 2,3-dioxygenase EC 1.13.11.11, indoleamine 2,3-dioxygenase EC 
1.13.11.52). However, when the oxygen atoms go to different substrates then these 
enzymes are called intermolecular dioxygenases (e.g. proline 3-hydroxylase EC 
1.14.11.28). The third class of dioxygenases (miscellaneous dioxygenases) includes 
several types of enzymes which are not well characterized but are essential for 
numerous metabolic reactions (e.g. tryptophan 2'-dioxygenase EC 1.13.99.3, see 
reaction below). More information about mono- and dioxygenases can be obtained 
from http://enzyme.expasy.org/.    
 


















1.3 Tryptophan metabolism 
 
L-Tryptophan is one of the nine essential amino acids that humans receive via their 
diet. Processing of L-tryptophan leads to three possible products; nicotinamide 
adenine dinucleotide (NAD+), serotonin, or protein synthesis (fig. 1.3).  
 
    
 
Figure 1.3: Tryptophan metabolism leads to three possible products; nicotinamide 
adenine dinucleotide (NAD+), serotonin or the biosynthesis of a new protein. 
 
 
According to its needs, human body uses a small proportion of L-Trp (~ 5%) for the 
production of neurotransmitter molecules (serotonin and melatonin) and the 
biosynthesis of new proteins while the rest ≥ 95% follows the kynurenine pathways 
for biosynthesis of NAD+ (10).  
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1.3.1 The serotonin pathway 
 
Via a pathway known as the serotonin pathway, L-Trp undergoes a number of 
structural modifications leading to serotonin and subsequently to melatonin (fig. 1.4). 
This minor pathway of L-Trp degradation has a major functional significance 
influencing a broad range of physiological systems including the central nervous 





Figure 1.4:  Chemical modifications of L-Trp in the serotonin pathway that lead to 
biosynthesis of serotonin and melatonin. 
 
 
In the initial step of the serotonin pathway, L-Trp undergoes hydroxylation at the 5’ 
position of the indole ring giving 5-hydroxy-L-tryptophan (5-OH-L-Trp). This 
reaction is catalysed by tryptophan hydroxylase, an iron-dependent enzyme that uses 
5,6,7,8-tetrahydrobiopterin (BH4) as co-factor. Following this, in a reaction catalysed 
by aromatic-l-amino acid decarboxylase, 5-OH-L-Trp undergoes decarboxylation 
producing 5-hydroxytryptamine or serotonin. Biosynthesis of serotonin triggers 
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melatonin production via a two-step process (12). During that process, serotonin 
undergoes N-acetylation of the amino group followed by o-methylation of the 5’-
hydroxyl group. These two reactions are catalysed by the enzymes N-




1.3.2 The kynurenine pathway 
 
The kynurenine pathway is the main route for L-Trp catabolism, leading to the 
production of nicotinamide adenine dinucleotide (NAD+). Nicotinamide adenine 
dinucleotide (NAD+) is an essential coenzyme for all living cells, and it is involved 
in a number of redox reactions (calcium homeostasis, energy metabolism, 
mitochondrial functions, gene expression, cell death and ageing) (13), (14). In addition 
to NAD+, the kynurenine pathway produces a number of active metabolites which 
are essential for homeostasis and will be described below. 
 The pathway is initiated by incorporation of molecular oxygen into L-Trp for 
production of N-formylkynurenine (fig. 1.5). This reaction is catalysed by one of 
three enzymes known as tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-
dioxygenase (IDO) and indoleamine 2,3-dioxygenase-2 (IDO2). Despite the fact that 
these enzymes catalyse the same reaction, their expression patterns and signalling 
pathways differ (10), (15). N-formylkynurenine is an unstable metabolite (in vitro) that 
is quickly transformed into L-kynurenine, the first stable product of the pathway. 
Kynurenine can subsequently be metabolized by three different enzymes for 
biosynthesis of kynurenic acid, anthranilic acid or 3-hydroxykynurenine. These 
enzymes are kynurenine aminotransferase, kynureninase and kynurenine hydroxylase 
respectively. Under normal conditions kynurenine hydroxylase has the highest 
affinity for kynurenine and therefore kynurenine is transformed into 3-






Figure 1.5: The enzymes and intermediates of the kynurenine pathway. 
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Kynurenic acid, under physiological conditions, is considered as an endogenous 
“neuroprotectant” which is found in the brain of mammals at nanomolar 
concentrations (17). As an antagonist to quinolinic acid, kynurenic acid acts on several 
receptors (N-methyl-D-aspartate receptor, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor and G protein-coupled receptor 35) inhibiting 
activation of intracellular enzymes, which are related with production of reactive 
oxygen species (ROS) (15). In contrast with kynurenic acid, 3-hydroxykynurenine and 
3-hydroxyanthranilic acid are toxic metabolites of the kynurenine pathway with 
established roles in DNA damage (18). Through a series of reactions these two 
intermediates can undergo auto-oxidation with the accompanying generation of 




Figure 1.6: Oxidation of 3-hydroxykynurenine and 3-hydroxyanthranilic acid is 
accompanied with production of reactive oxygen species.  
 
Production of 3-hydroxyanthranilic acid can be achieved either via the enzyme 
kynureninase (for which 3-hydroxykynurenine is a substrate) or the non-specific 
hydroxylation of anthranilic acid, a side product of the kynurenine pathway. At that 
point, 3-hydroxyanthranilic acid oxidase breaks the aromatic ring of 3-
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hydroxyanthranilic acid producing the intermediate 2-amino-3-carboxymuconic 
semialdehyde. This intermediate can follow two routes for biosynthesis of either 
picolinic acid or quinolinic acid.  The side branch which is responsible for 
production of picolinic acid is a two step pathway. More specifically, the enzyme 
amino-ß-carboxymuconate-semialdehydedecarboxylase converts the intermediate 
mentioned above to 2-aminomuconic semialdehyde with subsequent non enzymatic 
conversion to picolinic acid (19). In the main route, a non enzymatic rearrangement of 
2-amino-3-carboxymuconic semialdehyde allows the synthesis of quinolinic acid. 
While picolinic acid production is considered as beneficial, biosynthesis of 
quinolinic acid is thought to be detrimental. Studies on picolinic acid showed that it 
has neuroprotectant, antiviral and antimicrobial properties (19). On the other hand, 
quinolinic acid is related with activation of NMDA receptors (mentioned above), 
mitochondrial dysfunction and free radical generation (10). 
 
 
1.4 The kynurenine pathway in disease states 
 
 
As has become apparent from many years of studies, dioxygenation of L-Trp in the 
first step of the kynurenine pathway is the crucial point and rate-limiting step that 
influences the whole pathway. Whereas the implication of TDO/IDO/IDO2 in cancer 
will be discussed in the sections 1.5, 1.7 and 1.8, this section is focused on diseases, 
which are related with upregulation of these enzymes and accumulation of the 
kynurenine pathway metabolites. Examination of patients or animal subjects with 
inflammatory neurological diseases showed that accumulation of quinolinic acid is 
implicated in HIV infection (20), cerebral malaria (21) and ischemic brain injury (22). 
Moreover, direct intracerebral injection of quinolinic acid into rats causes neural 
death (23), (24). Some other kynurenine pathway metabolites, such as 3-
hydroxyanthranilic acid and 3-hydroxykynurenine, are normally present in the lens 
of the eye. These two molecules act as UV filters protecting the retina from UV light. 
However, accumulation of 3-hydroxyanthranilic acid and 3-hydroxykynurenine in 
the eye is related to the formation of free radicals that contribute to lens damage (25).  
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1.5 Tryptophan 2,3-dioxygenase (TDO) 
 
Tryptophan 2,3-dioxygenase (TDO), a cytosolic protein, is one of the three enzymes 
(along with indoleamine 2,3-dioxygenase (IDO) and indoleamine 2,3-dioxygenase-2 
(IDO2)) that catalyse L-tryptophan dioxygenation. Molecular oxygen is incorporated 
into L-tryptophan giving N-formylkynurenine as the product, in the first step of the 





Figure 1.7: Dioxygenation of L-Trp, a reaction catalysed by TDO, IDO and IDO2. 
 
 
Tryptophan 2,3-dioxygenase was initially isolated in 1936 by Kotake et al., who 
were working on the metabolic pathway of tryptophan in mammals (26). Because of 
the enzyme’s ability to cleave the pyrrole ring of tryptophan, it was initially named 
tryptophan pyrrolase, to be renamed later as tryptophan 2,3-dioxygenase. The gene 
responsible for the expression of human TDO protein is located on the long arm of 
chromosome 4 (4q31-q32) and it contains 12 exons (information about the TDO 
gene that has been used in the current thesis is given in section 2.3). The messenger 
RNA comprises 1693 nucleotides which in turn are translated into a functional 
protein of 406 amino acid residues (27). Although TDO is mainly expressed in the 
liver, it has been also found in the pituitary gland, embryonic tissue, mammary gland, 
bladder, muscle, eye, colon, lung, connective tissue, blood, brain, heart, testis, 
pancreas and skin after stimuli (27). TDO has been found in eukaryotes such as human 
(28), rat (29), rabbit (30) and prokaryotes like Ralstonia metallidurans (rmTDO) (31), 
Xanthomonas campestris (xcTDO) (32) and Pseudomonas fluorescens (pfTDO) (33). 
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While eukaryotic TDOs contain around 400 amino acids, prokaryotic TDOs are 
composed of ~300 amino acids. Among the prokaryotic TDOs that have been studied 
is xcTDO, the only solved TDO crystal structure with L-Trp bound (32). Its sequence 
identity with hTDO is 34% and the amino acid sequences of both xcTDO and hTDO 
are given in figure 1.8. Whilst the identities between prokaryotic and eukaryotic 
TDO sequences vary between 20-40 %, the sequence homology of human TDO with 
other members of that family, such as IDO, is not higher than 10 %. Despite the fact 
that the crystal structure of human TDO is not available as yet, the basic structural 
characteristics of the enzyme can be inferred through the knowledge gained from 
other TDOs (crystal structures of rmTDO (31) and xcTDO (32)). TDO is a 
homotetrameric protein that contains four b-type hemes, one in the active site of each 
monomer. More details about the available crystal structures and their characteristics 
are given in section 1.9. 
 
Xc_TDO -----------------MPVDKNLRD-LEPGIHTDLEGRLTYGGYLRLDQLLSAQQPLSE 42 
Hs_TDO MSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEKVLNAQELQSE 60 
                                            
 
Xc_TDO P---AHHDEMLFIIQHQTSELWLKLLAHELRAAIVHLQRDEVWQCR------KVLARSKQ 93 
Hs_TDO TKGNKIHDEHLFIITHQAYELWFKQILWELDSVREIFQNGHVRDERNMLKVVSRMHRVSV 120 
                           
 
Xc_TDO VLRQLTEQWSVLETLTPSEYMGFRDVLGPSSGFQSLQYRYIEFLLGNKN----PQMLQVF 149 
Hs_TDO ILKLLVQQFSILETMTALDFNDFREYLSPASGFQSLQFRLLENKIGVLQNMRVPYNRRHY 180 
                           
 
Xc_TDO AYDPAGQAR--LREVLEAPSLYEEFLRYLARFGHAIPQQY-------------------- 187 
Hs_TDO RDNFKGEENELLLKSEQEKTLLELVEAWLERTPGLEPHGFNFWGKLEKNITRGLEEEFIR 240 
 
 
Xc_TDO ---------QARDWTAAHVADDTLRPVFER--------------------------IYEN 212 
Hs_TDO IQAKEESEEKEEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSYRALQGALMIYFYRE 300 
                                    
                                    
Xc_TDO TDRYWREYSLCEDLVDVETQFQLWRFRHMRTVMRVIGFKRGTGGSSGVGFLQQALA--LT 270 
Hs_TDO EPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGGSSGYHYLRSTVSDRYK 360 
                             
 
Xc_TDO FFPELFDVRTSVGVDNRPPQGSADAGKR------------------ 298 
Hs_TDO VFVDLFNLSTYLIPRHWIPKMNPTIHKFLYTAEYCDSSYFSSDESD 406 
 
 
Figure 1.8: Amino acid sequences of xcTDO (top) and human TDO (bottom), with 
the identical and similar amino acids highlighted in red and blue respectively. These 
two enzymes share 34 % homology. 
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In terms of substrate selectivity, TDO can be considered as a highly selective enzyme 
that catalyses oxidation of L-Trp and a few other tryptophan derivatives like 5-
fluorotryptophan (34). In contrast with IDO, where its expression is induced by IFN-γ, 
TDO expression is trigged by glucocorticoid hormones and regulated by the 
availability of L-Trp (35). 
 Because of the neurotoxic properties of particular kynurenines, TDO was 
though to be implicated only in neurological disorders. However, a recent study has 
provided evidence for the implication of TDO in cancer biology, something which 
refreshes the interest in this specific enzyme (36). According to these findings, 
examination of glioma cancer cells revealed an increased level of kynurenine, purely 
synthesized by TDO. These kynurenine molecules serve as endogenous ligands for 
human aryl hydrocarbon receptor (AHR) which in turn promotes tumour-cell 
survival and motility. Moreover, an independent study of 104 human tumour lines, 
coming from Pilotte et al., showed the expression of TDO in 20 of them and the co-
expression of TDO and IDO in another 16 (37). All these findings clearly point out the 
important role of TDO in cancer biology and the need of developing new inhibitors 
for the enzyme. 
 
 
1.6 Indoleamine 2,3-dioxygenase (IDO) 
 
 
Indoleamine 2,3-dioxygenase (IDO) was first isolated from rabbit intestine and 
characterized in 1978 by Hayaishi et al. (38). In contrast with TDO, IDO can be found 
only in eukaryotes, and more specifically in mammals. It is a monomeric protein 
(M.W. = 45 kDa) composed of 403 amino acids and catalyses oxidation of L-Trp, D-
Trp, 1-Me-L-Trp and various tryptophan-like molecules. IDO is expressed in several 
tissues (but not the liver) and it is induced by IFN-γ. All the basic characteristics of 
IDO are presented in table 1.1 and compared with those of TDO (35). Despite the 




 IDO TDO 
reaction  Oxidation of L-tryptophan to N-formylkynurenine 
gene localization chromosome 8p12-p11 chromosome 4q31-q32 
subunits /size monomer (45 kDa) tetramer (191 kDa) 
found in eukaryotes prokaryotes and 
eukaryotes 
expression induced by IFN-γ glucocorticoid hormones 
distribution in the 
human body 
all tissues except liver mainly expressed in the 
liver 




L-Trp, D-Trp, 1-Me-L-Trp, 
5-F-Trp, 6-F-Trp, 




L-Trp, 5-F-Trp, 6-F-Trp 
 
 
Table 1.1: Comparison between IDO and TDO basic characteristics. 
 
 
1.7 The immunomodulatory role of IDO and TDO 
 
After the discovery of IDO, it was believed that the enzyme had mainly antimicrobial 
action because of its ability to control the availability of an essential amino acid in 
the inflammatory environment (39), (40). However, a groundbreaking discovery in 1998 
came to change ideas about the enzyme and its functions. That year, Munn and co-
workers reported that IDO action in pregnant mice prevented rejection of allogeneic 
foetuses, something which demonstrates an immunomodulatory role for the enzyme 
(41). This publication was the first among numerous others that relate IDO function 
with the immune system. In the years following, a number of new pieces of evidence 
came to show that IDO plays a key role in regulating immune evasion by tumours 
(42). The findings clearly showed that a variety of human tumours use IDO as a shield 
against the immune system. More specifically, it is found that IDO activation in 
patients with particular cancers is related to disease progression, low survival rates 
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and poor response against various chemotherapeutic and immunotherapeutic agents 
(42). Despite the fact that TDO was likely to be involved in cancer biology, the 
finding could not prove it. Thanks to the discovery of Opitz et al. (36) both IDO and 
TDO have been formally associated with cancer. The immunosuppressive role of 
TDO and IDO is based on two theories (43); the tryptophan starvation theory and the 
tryptophan metabolite theory. According to the first theory, it has been proposed that 
the enzymes could have similar effects on T cells as they have on bacteria.  In this 
way depletion of tryptophan increases the sensitivity of T lymphocytes driving them 
to apoptosis (43). After this hypothesis Frumento et al. examined in vitro models of T 
cell activation in the presence and absence of L-Trp. Interestingly, they observed that 
lack of L-Trp did not affect T cell proliferation (44). This finding, in combination with 
the fact that reduced levels of L-Trp can rapidly be replenished by diffusion from 
surrounding tissues, makes tryptophan starvation less likely to occur in vivo. In 
contrast with the first theory, the tryptophan metabolite theory implicates tryptophan 
catabolic metabolites such as kynurenine, 3-hydroxykynurenine, 3-
hydroxyanthranilic acid and quinolinic acid in apoptosis of T cells. In section 1.5, it 
was shown that kynurenine serves as endogenous ligand for human aryl hydrocarbon 
receptor (AHR), which in turns promotes tumour survival. This serves to reinforce 
the second scenario. While the precise mechanism of TDO and IDO action remains 
to be determined, both theories can plausibly explain T-cell survival and action. 
  
 
1.8 Indoleamine 2,3-dioxygenase-2 (IDO2) 
 
Indoleamine 2,3-dioxygenase-2 (IDO2) is a third enzyme that catalyses oxidation of 
L-tryptophan in the first step of the kynurenine pathway. IDO2 is encoded by a gene 
which is located on chromosome 8 (8p11.21) and presents a tail-to-head arrangement 
with IDO. Because of its position and transcriptional function, LOC169355 (as it was 
known before 2007) was renamed to IDO2 (45). The full length protein product 
(human IDO2) comprises 420 amino acids and it shares 72% identities with mouse 
IDO2, 45% identities with mouse IDO and 44% identities with human IDO (46). 
Regarding its expression pattern, it has been found that human IDO2 is expressed in 
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a subset of tissues that express IDO. While IDO mRNA is found in various tissues, 
IDO2 mRNA is detected only in liver, small intestine, spleen, placenta, thymus, lung, 
brain, kidney, and colon (45). As reported in section 1.6, IDO expression is strongly 
induced by IFN-γ, something which has not been confirmed for IDO2. A study on 
mice demonstrated that during malaria infection IDO and IDO2 are induced in 
different tissues (endothelium and kidney respectively) and in contrast with IDO, the 
expression levels of IDO2 are not influenced by the presence of IFN-γ (46). IDO2 
localization on chromosome 8, in combination with its reduced catalytic efficiency 
could suggest that the enzyme is the product of gene duplication. Nevertheless, the 
distinct characteristics of hIDO2 reinforce the possibility of it having a new 
immunomodulatory role. Studies on mice showed that both IDO and IDO2 are 
expressed in particular tissues (e.g. epididymis), supporting the idea of IDO2 
implication in an unidentified signalling pathway (47).  
  Like IDO and TDO, IDO2 has an active role in cancer biology. In 2009, Löb 
et al. first implicated IDO2 in cancer, showing expression of the enzyme in gastric, 
colon and renal tumours (48). After these findings, an independent study from 
Sørensen et al. came to verify the importance of IDO2 in tumour escape and survival 
(49)
. According to their work, in peripheral blood samples obtained from both healthy 
donors and cancer patients, there was noticed a spontaneous cytotoxic T-cell 
reactivity against IDO2. These T cells were shown to be cytotoxic effector cells that 
recognize and kill tumour cells (49). Although IDO2 is a relatively newly discovered 













1.9 The crystal structures of TDO and IDO proteins 
 
Crystal structures of two TDOs and one IDO have been reported so far. While the 
two TDO structures come from bacterial species, Ralstonia metallidurans TDO 
(rmTDO) (31) and Xanthomonas campestris TDO (xcTDO) (32), the IDO structure is 
from Homo sapiens (hIDO) (50). Details regarding these crystal structures are 
presented in table 1.2.  
 




None, L-Trp, 6-F-Trp 
 
































1.9.1 TDO crystal structure 
 
 
X. campestris TDO (xcTDO) and R. metallidurans TDO (rmTDO) share 47% 
sequence identity (51). Despite the fact that both of these are bacterial enzymes and 
share less than 40 % identity with the human TDO, the xcTDO structure in particular 
provides great insight into the structure-function relationship. In contrast with 
rmTDO, xcTDO has been crystallised in the ferrous active form with the substrate 
bound, something crucial for better understanding of the enzyme and its function. In 
addition to this, the xcTDO structure is at a higher resolution. For those reasons, 
xcTDO will be the only TDO structure discussed below. Each TDO monomer is 
composed of twelve α-helices (αA-αL) and no β-strands (32) (fig. 1.9). Helices αB 







Figure 1.9: Illustration of the xcTDO monomer and dimer. The monomer is 
composed of twelve α-helices, and part of helix αA of one monomer contributes to 
formation of the substrate binding site in the adjacent monomer, leading to a ‘dimer 
of dimers’ arrangement for the tetramer (taken from ref. 51 and 52). 
 
 
In addition to those regions forming the tetramer interface it is interesting to observe 
that adjacent monomers are intimately associated via a segment of 20 residues from 
their N-termini, including helix αΑ (fig 1.9) (32). A number of these residues have 
essential involvement in active site functionality. With this in mind the TDO tetramer 
is perhaps best described as a dimer of dimers. Similar to helix αA, the helices αB 
and αD and loops αD-αE and αJ-αK play an important role in substrate binding and 
stability. More specifically, the carboxyl group of L-Trp displays an ion-pair 
interaction with arginine 117, and is hydrogen bonded to tyrosine 113 and threonine 
254 (fig. 1.10). The substrate ammonium group is recognized by the 7-propionate 
group of the heme, while also forming hydrogen bonds with threonine 254 and a 
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water molecule that is present in the active site of the binary complex. The nitrogen 
atom of the indole ring is hydrogen-bonded to histidine 55, a conserved amino acid 
in all TDOs. Finally, the indole ring is held in place and stabilized by van der Waals 
interactions with a number of hydrophobic amino acids. Some of those, such as 
tyrosines 24 and 27, and leucine 28, come from the N- terminal segment of the 





Figure 1.10: XcTDO active site and the interaction with L-Trp (taken from ref. 52) 




Four of these are located in the active site of each monomer, while the other four are 
in the area of the tetramer interface (fig. 1.11). Binding of L-Trp in the interface area 
of the tetramer could suggest a potential allosteric role. Nevertheless the enzyme’s 
kinetic findings showed no allosteric effect (32), and as such any allosteric behaviour 







Figure 1.11: The xcTDO tetramer and the eight L-Trp binding sites. Four L-Trp 
molecules bind in the active sites of the four monomers while the other four can be 


















1.9.2 IDO crystal structure 
 
 
The crystal structure of human IDO was published in 2006 by Sugimoto et al., and it 
is the only eukaryotic IDO structure available (50). Despite this important discovery, 
the structure yields little information about the substrate’s interactions at the active 
site. Both of the ligands present in the structures of IDO, 4-phenylimidazole (4-PI) 
and cyanide (CN-), are inhibitors of the enzyme, binding to the heme iron. The 
crystal structures of IDO in complex with 4-phenylimidazole and cyanide were 
solved at 2.3 and 3.4 Å respectively and for this reason only the 4-PI-bound structure 
will be discussed below.  
 The human IDO monomer can be considered as two domains; the large (C-
terminal) and the small (N-terminal) domains (fig. 1.12). The large domain is shown 
in green, the small one in blue. In a cavity between them lies the heme moiety 





Figure 1.12: IDO crystal structure with 4-PI bound (taken from ref. 50)  
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The large domain of hIDO is composed of 13 α-helices and two 310 helices while the 
small domain consists of six α-helices, three 310 helices and two β-sheets. The 
domains interact via helices K, L and N, which are shown in cyan, and are joined 
together via a loop region (shown in red) which lies above the sixth coordination site 
of the heme.  
 In the active site of the 4-PI-bound structure the ligand is surrounded by a 
number of polar and non polar amino acids (fig. 1.13). One of the helices of the large 
domain, helix Q, interacts directly with the heme iron providing an imidazole group 
(the side chain of His 346) as endogenous ligand. In order to probe the roles of some 
of these residues, site-directed mutagenesis of Ser167, Cys129 and Phe163 to alanine 
(S167A, C129A and F163A) showed no significant effect on enzyme activity and 
thus providing information regarding the function of these amino acids in the 
catalytic mechanism (50). In contrast, substitution of Phe226 and Arg231 by alanine 
(F226A and R231A) caused a dramatic drop in the enzymatic activity, suggesting the 
involvement of these amino acids in L-Trp recognition. More specifically, mutation 
of Phe226 and Arg231 had as consequence the drop of the activity (kcat/Km) by a 




Figure 1.13: The IDO active site in the presence of a heme-specific inhibitor 4-
Phenylimidazole (taken from ref. 52)  
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1.10 Binary and Ternary complexes in TDO and IDO 
 
 
Formation of the catalytically-active TDO ternary complex (Trp-Fe2+-O2) has been 
proposed to be an ordered process with L-Trp binding first, then O2 
(32). 
Electrochemical studies have shown that ferrous TDO does not form a stable 
complex with dioxygen (34), while the ferric form does not bind dioxygen. In 
addition, when the heme iron is in the inactive, ferric form, substrate binding is 
disfavoured with respect to the ferrous form (32). Reduction of TDO/IDO has been 
studied both in vitro and in vivo. In vitro reduction of TDO/IDO can be achieved via 
ascorbic acid and methylene blue (53). In vivo, cytochrome b5 has been proposed to 
fulfil this role (54). In comparison with TDO, IDO appears to react with specific 
oxygen species in both ferrous and ferric forms. In contrast with TDO, IDO can bind 
either L-Trp or dioxygen first to form two distinct stable binary complexes (51). 
Subsequent binding of dioxygen or L-Trp respectively will lead to the formation of 
the ternary complex. This is not the only difference between TDO and IDO. At the 
end of each catalytic cycle, IDO undergoes auto-oxidation, something that does not 
happen with TDO (55). Therefore the continual re-reduction of IDO is a precondition 
for activity. Formation of the binary and ternary complexes is explained further in 
the following diagram (fig. 1.14). 
 
 
Figure 1.14: Formation of the binary and ternary complexes in TDO 
(I→II→IV→V) and IDO (both routes). 
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1.11 Catalytic Mechanism 
 
The catalytic mechanism of N-formylkynurenine formation has been the subject of 
research for many years. Despite the fact that study of heme dioxygenases has 
continued for more than 70 years, since the discovery of TDO (26), the reaction 
mechanism of both TDO and IDO is still not clarified. As figure 1.15 illustrates, the 
first step of TDO and IDO dioxygenation can proceed via either an ionic or a radical 
mechanism. According to the first proposed mechanism (fig. 1.15A) (55), 
dioxygenation of tryptophan involves the action of an active site base. This active 
site base could be either an active site residue like histidine, or a water molecule, and 
serves as a nucleophile, abstracting a proton from the indole nitrogen. The base-
catalysed deprotonation of the indole nitrogen can proceed via an ionic mechanism 
and demands the base to be in an appropriate position. The publication of the xcTDO 
crystal structure in 2007 revealed that the base-catalysed mechanism using a water 
molecule is unlikely because there is none present in the active site when L-Trp is 
bound (32). From the currently available crystal structure of IDO, the occupancy of 
solvent in the active site upon substrate binding is unclear (50). Despite this, the 
crystal structure of xcTDO has a histidine residue (His55) in an appropriate position 
that could serve the role of a base. The hIDO structure, on the other hand, contains a 
serine residue (Ser167) at the corresponding position, raising further questions (50). 
Single point mutations of both Ser167 in IDO, and His55 in TDO, showed that 
neither of these are essential for catalytic activity, thus making a base-catalysed 
mechanism involving a protein-derived active site base unlikely (56, 57). 
 
Figure 1.15: Oxygen activation proceeds via one of the four potential routes; (A) 
Base-catalysed, (B) concerted oxygen-ene, (C) direct electrophilic addition, (D) 
radical addition at (i) C2 or (ii) C3 (taken from ref. 60) 
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After the abandonment of the first scenario, it was proposed that dioxygen could play 
the role of the active site base in an “oxygen-ene”-type reaction (fig. 1.15B) (50). This 
reaction mechanism was initially suggested because 1-methyltryptophan (1-MT) was 
found to be an inhibitor of IDO. In this way the methylation of the indole nitrogen is 
expected to prevent the initial deprotonation step and, therefore, turnover. However, 
it has been shown that while N-methylation affects the enzyme’s catalytic activity, 1-
MT can also serve as a substrate. These findings show that deprotonation of the 
indole nitrogen is not essential for activity and therefore reveals the weakness of the 
“oxygen-ene” type reaction (58).  
 Consequently, direct electrophilic addition of dioxygen is one of the two most 
likely mechanisms. Instead of deprotonation, the lone pair electrons of nitrogen can 
initiate the reaction as figure 1.15C illustrates. Addition of oxygen to either the C2 or 
C3 position of the electron-rich indole ring seems to be favourable. Regarding the 
last potential route (a radical mechanism), catalysis can proceed via direct addition of 
O2 either to the C3 position or the C2 position of L-Trp (fig. 1.15D). Although both 
electrophilic and radical addition are the most likely to occur, neither is well-
established. 
 Instead of incorporation of both oxygen atoms simultaneously, the most 
recent findings support the idea that dioxygen inserts into tryptophan in steps (59, 60). 
Both of the last two oxygen activation processes (electrophilic and radical) are 
consistent with the mechanism proposed in figure 1.16. According to this 
mechanism, either electrophilic or radical routes lead to the formation of a ferryl 
heme species with concomitant formation of an epoxide intermediate species. The 
formation of a ferryl heme intermediate was first detected by Yeh and co-workers 
using resonance Raman methodology (61). The epoxide intermediate was detected 
indirectly using mass spectrometry experiments (59). During this study, Raven and co-
workers identified a cyclic aminoacetal structure (m/z = 221) which was proposed to 
be a byproduct of the reaction that originates from collapse of the initially formed 
(and unstable) 2,3-epoxide by monooxygenation of L-Trp. In the proposed 
mechanism in fig 1.16, ring-opening of the epoxide intermediate is followed by the 
insertion into the indole ring of the second oxygen atom, and then ring cleavage for 








Figure 1.16: The proposed mechanism for N-formylkynurenine formation (59-61) 
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1.12 Inhibition studies 
 
 
Inhibition of tryptophan dioxygenation in the first step of kynurenine pathway is of 
great interest to the pharmaceutical and medical communities, not only because of 
the rate-limiting nature of the reaction over the whole kynurenine pathway, but also 
because it manages the amount of L-Trp used for biosynthesis of neurotransmitter 
molecules (serotonin, melatonin). With the implication of roles for TDO (36), IDO (42) 
and IDO2 (48, 49) in cancer, the potential need for development of drugs to target these 
enzymes has arisen. While IDO2 is a newly-discovered enzyme with an unexplained 
catalytic behaviour (the turnover rate with L-Trp as substrate is unlikely to represent 
biologically-relevant activity) (62), only inhibitors of the well-studied TDO and IDO 
will be discussed. In the case of TDO, at this point it can be said that the list of 
identified inhibitors is not so impressive. This is likely due to the fact that TDO’s 
immunomodulatory action was ambiguous until 2011 (36). Nevertheless, the most 
potent TDO inhibitors published so far belong to the family of 3-(2-pyridylethenyl)-
indoles, with inhibition constants between 30-100 nM (fig. 1.17) (63), (64). Among the 
3-(2-pyridylethenyl)-indoles that are shown below, 3-pyridyl and 4-pyridyl revealed 
the highest inhibition potency with inhibition constants of 40 nM and 30 nM 
respectively (63). Most of the substitutions that had been introduced to these structures 
had a detrimental effect on TDO inhibition activity, especially substitutions at the 
indole-nitrogen. However, fluorine substitution in the 5 or 6 position of the indole 
ring was found to be well tolerated, conserving the inhibition constants between 30 
nM and 50 nM (63).  
 
 
Figure 1.17: 3-(2-pyridylethenyl)-indoles as specific TDO inhibitors. 
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In contrast with TDO, the list of IDO inhibitors is longer and has greater chemical 













Norharman (or β-carboline) is among the first published IDO inhibitors (65), with 
kinetic studies using rabbit intestinal IDO yielding an inhibition constant of 120 µM. 
Five years after the discovery of norharman, it was shown that the molecule is a 
competitive inhibitor of IDO, binding to the heme iron (66) (fig. 1.19). Despite the 
fact that the author of the original study reported norharman as a non-competitive 
inhibitor of IDO, its competition with O2 for binding to the heme iron demonstrates a 




Figure 1.19: Inhibition of IDO by Norharman (66) 
 
 
Two years after the identification of norharman as a non-specific heme binding 
inhibitor of IDO, Sono and co-workers published the discovery of a new IDO 
inhibitor, 1-methyltryptophan (1-MT) (67). 1-MT is a tryptophan analogue with a 
methyl group on the nitrogen of the indole ring (fig. 1.18). Because of its structure, 
1-MT is a competitive inhibitor of L-Trp with an inhibition constant of 34 µM (68). It 
exists in two stereoisomeric forms, 1-methyl-L-tryptophan (1-Me-L-Trp) and 1-
methyl-D-tryptophan (1-Me-D-Trp), each of which has unique inhibition behaviour 
against IDO. Among the IDO inhibitors that have been reported up to date, 1-MT is 
the most famous and well-studied. This is related with the favourable 
pharmacokinetic characteristics of the molecule, such as oral availability, low 
toxicity, low clearance and low protein binding (69). In addition to those 
characteristics, 1-MT is a selective IDO inhibitor with no inhibitory activity against 
TDO. As the model in figure 1.20 illustrates, the active site of xcTDO contains a 
histidine residue (His55), which in the presence of L-Trp forms hydrogen bonds with 
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the nitrogen of the indole ring. Methylation of the indole nitrogen may disrupt this 
hydrogen bonding causing a clash of the histidine residue with the methyl group of 
1-MT. This phenomenon does not occur in IDO because the equivalent amino acid is 
serine (Ser167). Despite the favourable pharmacokinetic characteristics of 1-MT, in 
vivo studies showed that it can retard tumour growth but not prevent progression (43). 
These findings raised concerns about its usefulness as monotherapeutic drug. 
Combination of 1-MT with other chemotherapeutic drugs showed that the molecule 
can act synergistically for inhibition of IDO (70), but as yet only 1-Me-Trp (1MT) has 
been used in clinical trials. Conflicting results show that the function of 1-Me-Trp in 
vivo is not fully understood (70). While 1-Me-Trp exists as two stereoisomers (D-, L-), 
it is unclear what the effect of each isomer is in the human body. 
 
 
Figure 1.20: (A) The crystal structure of xcTDO with L-Trp bound (32). (B) A model 
that is based on the published crystal structure (A) and explains the potential 
orientation of 1-MT in the active site of xcTDO. The methyl group of 1-MT clashes 
with the active site residue His55 causing steric effect. The models (C) and (D) 
propose the potential binding of L-Trp (C) and 1-MT (D) in the active site of hIDO. 
The presence of Ser167 (hIDO active site) allows 1-MT to interact with the IDO 
active site, something which cannot occur in TDO due to the presence of His55 (The 








(C) (D) Ser 167 
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 In vitro examination of the two stereoisomers revealed that the L-enantiomer is a 
significantly better inhibitor of hIDO than the D-enantiomer. 1-Methyl-L-tryptophan 
is found to inhibit IDO with Ki = 19 µM while 1-methyl-D-tryptophan has no effect 
at concentrations up to 100 µM (71). However, in vivo studies showed a significantly 
higher efficiency of the D-isomer in reversing the suppression of T cells. Studies on 
mice demonstrated that 1-Me-D-Trp is more effective as an anticancer agent in 
chemo-immunotherapy regimens using particular chemotherapeutic agents (71). These 
findings clearly show the implication of the D-enantiomer in cancer biology. The 
antitumour property of 1-Me-D-Trp could not be explained until the discovery of 
IDO2, leading to the suggestion that the inhibitory action of 1-Me-D-Trp could be 
related with IDO2. The presence of hIDO2 mRNA in particular cancers, in 
combination with its distinct characteristics indicates a potential immunomodulatory 
role which is unrelated to that of IDO. Inhibition findings show that 1-Me-D-Trp 
inhibits IDO2 but it is ineffective against recombinant IDO (72).  
 Attempts to identify other inhibitors of IDO, with higher potency than 1-MT, 
led to interest in methylthiohydantoin-DL-tryptophan (MTH-Trp) or necrostatin-1. 
MTH-Trp is a competitive inhibitor of IDO with an inhibition constant of 11 µM (68). 
Cell-based assays showed that the molecule is 20-fold more potent than 1MT, more 
soluble in aqueous solution and more rapidly cleared from serum. In terms of the oral 
bioavailability of MTH-Trp, it has been found that is equally as available as 1-MT 
(68).  
 Another class of IDO inhibitors is related to the plant extract brassinin (73). 
Brassinin is natural occurring product with anticancer properties. Brassinin and its 5-
bromo substituted derivative behave as competitive inhibitors of IDO with inhibition 
constants of 28 µM and 25 µM respectively (73). Cell-based assays showed that both 
brassinin and 5-bromo-brassinin are bioavailable inhibitors of IDO with EC50 (half 
maximal effective concentration) values of 38 µM and 24 µM respectively. 
 Another large set of IDO inhibitors are naphthoquinone-based. The idea of 
developing naphthoquinone-based inhibitors was taken from the natural product 
menadione (fig. 1.21), which was found to be active in mouse tumour models, 




Figure 1.21: Representative naphthoquinone-based inhibitors that were used by 




Screening of these molecules demonstrated that motifs such as 1,2-naphthoquinone 
or 1,4-naphthoquinone are essential for IDO inhibition (fig. 1.21). Substitutions on 
either benzene or quinone rings do not eliminate the inhibition potency of the 
molecule. In contrast, the benzoquinone derivatives were inactive, highlighting the 
necessity of a benzene-quinone structure for activity as an IDO inhibitor. The results 
of this study showed that these molecules behave as non-competitive inhibitors with 
inhibition constants significantly lower than those reported for 1-MT, MTH-Trp and 



















Within the list of IDO inhibitors there are a series of natural products coming from 
the marine hydroid Garveia annulata. Among those molecules that have been 
identified as IDO inhibitors are annulin A, B and C (Ki = 690 nM, 120 nM and 140 
nM respectively), 2-hydroxygarveatin E (Ki =1.4 µM) and garveatin A, C and E (Ki 









Like annulins, mitomycin C also contains the benzoquinone moiety (fig. 1.18). 
Mitomycin C is another natural occurring product, isolated from Streptomyces, with 
well-studied chemotherapeutic properties. It is believed that its antitumour potency is 
related to the ability of mitomycin C to form interactions with DNA. These 
interactions could be either interstrand (between two adjacent DNA strands) or 
intrastrand (between two points of the same DNA strand) (76). The consequence of 
this cross-linking is the inhibition of DNA synthesis. Because of this property, 
mitomycin C is approved, by FDA, to be used alone or with other drugs for treatment 
of gastric (stomach) and pancreatic adenocarcinoma. More details about the molecule 
can be found at http://www.cancer.gov/cancertopics/druginfo/mitomycinc. In 
addition to this, mitomycin C (fig. 1.18) is also a reported IDO inhibitor. Findings 
show that the molecule inhibits IDO in an uncompetitive fashion with an inhibition 
constant of 25 µM (77). In vitro screening for identification of new IDO inhibitors 
revealed another natural product with high inhibition potency. Exiguamine A, a 
methanol extract of the sponge Neopetrosia exigua, was found to inhibit IDO with Ki 
= 210 nM (78). Based on the fact that exiguamine A combines some of the structural 
characteristics of tryptamine and annulin C (fig. 1.23), a number of new IDO 
inhibitors were synthesized with structures more simple than exiguamine A. 
Consequently, the newly-synthesized IDO inhibitors revealed inhibition potencies 
between 190 nM and 10.9 µM (79).  
 
 
Figure 1.23: Exiguamine A combines structural features of tryptamine and annulin C. 
 35 
In the same list of IDO inhibitors, ebselen should be included. Ebselen, which is also 
known as 2-phenyl-1,2-benzisoselenazol-3(2H)-one, is found to inhibit IDO with an 
inhibition constant of 94 nM (80). Experimental results showed that the molecule 
reacts with multiple cysteine residues of IDO, something which inactivates the 
enzyme (fig. 1.24). However, removal of ebselen can reverse the inhibition effect, 
restoring IDO enzymatic activity.  These findings suggest that some cysteine 

























The implication of TDO and IDO in severe disorders, including tumour growth, is 
well documented. In the last few years attention has begun to focus on the 
development of compounds that could inhibit the action of these enzymes. Numerous 
inhibitors have been reported so far but only one has been used in clinical trials. 
Despite its favourable pharmacokinetic characteristics and the specificity against 
IDO, 1-MT is not the ideal inhibitor. Whereas 1-MT is found in two stereoisoforms, 
it is unclear how each stereoisomer behaves against IDO and IDO2.  The actual 
inhibition potency of 1-Me-L-Trp and 1-Me-D-Trp in vivo is yet to be evaluated. The 
early identification of IDO as an immunomodulatory enzyme focused interest in the 
development of IDO inhibitors, while TDO was considered to be of much lower 
priority. This is particularly obvious if we consider that the best TDO inhibitors 
published were published in the 1990s, with little recent literature forthcoming. 
 The aim of this thesis is to identify novel inhibitors for both IDO and TDO 
that can be used as template for the development of a new class of therapeutic agents. 
As a starting point, published hTDO and hIDO were evaluated. Using the knowledge 
gained from previous studies, and the recently available structural knowledge of 
TDO and IDO, a series of potential inhibitors was screened and characterised. 
Central to this approach was the kind provision of access to the chemical repository 
collection of synthetic molecules and pure natural products held by the National 
Cancer Institute (USA). 
 In addition to this, characterisation of the selectivity of 1-MT inhibition is 
another major subject of the thesis. The recent discovery of IDO2 and its reported 
expression in particular cancers has raised a lot of questions about its biological role. 
Despite that, the fundamental biochemical characteristics of the enzyme are still to be 
assessed. Through the in vitro biochemical characterization of IDO2, the potential 
biological role of the enzyme in terms of substrate specificity and 1-MT inhibition 
selectivity will be evaluated. The findings will be compared with the corresponding 
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Materials and Methods 
 
 
2.1 Materials  
 
Most of the chemicals used (L-Trp, D-Trp, L-ascorbate, bovine liver catalase, 
methylene blue, inhibitors and tryptophan analogues) including those for buffers 
(Sigma-Aldrich) were of the highest analytical grade (≥97% purity) and were used 
without further purification. 1-Me-L-Trp and 1-Me-D-Trp (95% purity, Sigma-
Aldrich) were purified further as described below. Inhibitors obtained from the 
National Cancer Institute, USA, were used as received. Details about the purity of 




2.2 High-performance liquid chromatography (HPLC) 
 
 
Further purification of 1-Me-L-Trp and 1-Me-D-Trp (95% purity as purchased from 
Sigma-Aldrich) demanded usage of high-performance liquid chromatography 
(HPLC). The whole procedure was based on a previous published protocol (1). Before 
the initiation of the purification process, 1-Me-L-Trp and 1-Me-D-Trp were 
dissolved in 90 % H2O -10% MeCN, at final concentrations between 1-2 mM, and 
the resulting solution filtered using Millipore syringe filters (0.22 µm pore size). Two 
litres of the running buffer, 90 % H2O -10% MeCN, were also filtered and sonicated 
for removal of contaminants and air bubbles. Prior to loading the sample, the reverse 
phase C18 column (250 × 4.6 mm) was preincubated with at least 1 CV of the 
running buffer (90 % H2O -10% MeCN). The UV detectors and temperature were set 
at 280 nm and 25 oC correspondingly. The sample’s injection volume and flow rate 
were adjusted to 1ml and 1ml/min respectively and the pure 1-Me-L-Trp/ 1-Me-D-
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Trp peak was eluted after ~17 min (fig. 2.1). The purified 1-Me-L-Trp/ 1-Me-D-Trp 
sample was confirmed via mass spectrometry analysis which was carried out at 
University of Edinburgh, School of Chemistry by the MS service. Important to be 
reported is that the retention time of 1-Me-L-Trp/ 1-Me-D-Trp peak could easily be 






















2.3 Plasmids, expression strains, and storage 
 
 
The full-length human IDO (hIDO) construct fused into a ToPO plasmid (Invitrogen) 
was expressed using BL21 (DE3) E. coli cells, with a 6-His tag at the N-terminus. 
The coding region of human TDO (hTDO), ligated into a pET28a plasmid, was 
expressed using Rosetta (DE3) plysS cells, having a 6-His tag in the C-terminus. The 
plasmids for expression of hTDO and hIDO were kindly provided by Prof. Emma L. 
Raven, University of Leicester, UK (2). The full-length human IDO2 (hIDO2) 
construct was fused into a pDEST plasmid (Invitrogen) and expressed using BL21 
(DE3) E. coli cells, with an N-terminal 6-His tag. The plasmid for expression of 
hIDO2 was kindly provided by Dr. Helen J. Ball, University of Sydney, Australia (3). 
For long term storage of each expression strain 930µl of E. coli culture media were 
mixed with 70 µl dimethyl sulfoxide (DMSO) and stored at -80 oC. All the 






















































2.4 Growth and expression 
 
Bacterial strains containing the hTDO, hIDO or hIDO2 encoding plasmids were 
cultured in Luria Bertani broth (10 g tryptone, 5 g yeast and 10g NaCl dissolved in 
1L H2O), also known as LB, previously sterilised by autoclaving at 121 ºC for 20 
minutes. Starter cultures for large scale growth were prepared by inoculating 20 ml 
of sterile LB media (supplemented with 100 µl of the appropriate antibiotic) with 
some of the DMSO cell stock via a sterile pipette tip. For hIDO and hIDO2, the 
antibiotic used was 100 µl of 25 mg/ml amplicillin while for hTDO, 100 µl of 25 
mg/ml kanamycin. The mixture of sterile media, antibiotic and E. coli expression 
strain was then incubated for 24 hours at 37 ºC with shaking at 225 rpm. For large 
scale growth, flasks containing 600 ml LB broth were inoculated with 1 ml of starter 
culture and either 500 µl of 25 mg/ml amplicillin (hIDO and hIDO2) or 500 µl of 25 
mg/ml kanamycin (hTDO). Flasks were incubated with shaking at 37 ºC and 200 rpm 
until the OD600 reached 0.6. Protein production was then induced by addition of 
isopropyl-β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 250 mgl-1. 
The culture medium was supplemented with 0.5 ml of 5 mM hemin solution per flask 
to maximize heme incorporation. The temperature was also decreased to 22 ºC and 
left for a further 12 hours with shaking at 135 rpm until the cells were harvested by 
centrifugation (10 minutes at 8000 rpm) using a Sorvall RC-5B refrigerated 
centrifuge at 4 ºC. The resulting cell pellets were either lysed and the protein purified 





















2.5.1 Buffers used during the extraction and purification processes 
 
 
Buffer A (lysis buffer):  i) 20 mM TrisHCl buffer pH 8.0,  
                                        ii) 300 mM in NaCl,  
                                       iii) 10 mM in imidazole,  
                                       iv) 1mM in tris(2-carboxyethyl)phosphine (TCEP)  
 
Buffer B (washing buffer):  i) 20 mM TrisHCl buffer pH 8.0,  
                                               ii) 300 mM in NaCl,  
                                              iii) 20 mM in imidazole,  
                                              iv) 1mM in tris(2-carboxyethyl)phosphine (TCEP)  
 
 
Buffer C (elution buffer):  i) 20 mM TrisHCl buffer pH 8.0,  
                                             ii) 300 mM in NaCl,  
                                            iii) 250 mM in imidazole,  
                                            iv) 1mM in tris(2-carboxyethyl)phosphine (TCEP)  
 
 
Buffer D (storage buffer):  i) 20 mM TrisHCl buffer pH 8.0,  













2.5.2 Cell lysis 
 
 
The harvested cells were resuspended in buffer A, and cell lysis was initiated by 
incubating 200ml of cell suspension for 30 minutes with hen egg white lysozyme (1 
mg per ml of suspension), phenylmethylsulfonyl fluoride (PMSF) (2 mg per ml of 
suspension) and 1 complete protease inhibition tablet (Sigma). Lysis was completed 
by ultrasonication of the suspension on ice. Cell debris was then removed via 
centrifugation for 1 hour at 20000 rpm and 4 ºC, and the supernatant collected.  
 
2.5.3 Chromatographic purification 
 
For purification of hIDO or hIDO2, the supernatant (~200-250 ml) from the previous 
step was loaded onto a Ni-agarose column previously equilibrated with buffer A. In 
contrast, the hTDO-containing supernatant was loaded onto a Ni-agarose column in 
batches of 100 ml. Reduction of the loading volume was necessary in order to avoid 
protein aggregation onto the column. hIDO and hIDO2 proteins were washed with 5 
column volumes (CV) of buffer B and eluted using the same buffer but containing a 
higher concentration of imidazole (buffer C- elution buffer). hTDO protein was 
washed using 30-50 ml of buffer B and eluted in the same way. Size exclusion 
chromatography (either Superdex 75 for hIDO and hIDO2 or Superdex 200 for 
hTDO) was also used in order to remove imidazole (information about the elution 
times of hTDO and hIDO2 are given in Appendix F). The column was pre-
equilibrated with buffer D for at least 1 CV and the proteins collected were judged to 
be pure and homogeneous. The imidazole-free proteins were then concentrated by 
centrifugation using Amicon Centricon filter devices of either 30 kDa molecular 
weight cut off (MWCO) for hIDO and hIDO2 or 100 kDa MWCO for hTDO. The 
diluted proteins were centrifuged at 2500 rpm until they reached concentrations 
between 150 and 400 µM; hTDO and hIDO2 up to 150 µM, hIDO up to 400 µM (for 
calculation of proteins concentration see section 2.6.3). Aliquots of 200-400 µl 
hTDO, hIDO and hIDO2 proteins were flash frozen in cryovials using liquid nitrogen 
and stored at -80 ºC until required. 
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2.6 Purity determination 
 
 
2.6.1 SDS-PAGE analysis 
 
Sample preparation requires denaturation of the proteins. To accomplish this an 
Eppendorf tube containing 25 µl SDS sample buffer (TrisHCl, SDS, glycerol, β-
mercaptoethanol and bromophenol blue), 75µl water and 1 µl protein sample was 
boiled for about 3 minutes. Following this a small volume of the mixture (~10-20 µl) 
was loaded onto a pre-poured 4–12 % Bis-Tris gel (Invitrogen). The gel tank was 
filled with running buffer and the voltage was set at 150 V for approximately one 
hour. At the end of this process, the gel was removed from the tank and stained for 
total protein content. 
 
 
2.6.2 Coomassie staining 
 
Post-electrophoresis gels were soaked in Coomassie Brilliant Blue G-250 for about 
15 minutes to stain the sample blue (through the interaction of Coomassie blue with 
arginine and histidine residues and the aromatic amino acids of the protein). The gel 
was then washed with water and destained with a mixture comprised of 10% glacial 
acetic acid, 40% MeOH and 50% water. The gel was kept in the destaining solution 
for 3-4 hours or until bands were visible. An example of hTDO staining can be 
observed in figure 2.2. The first lane is occupied by molecular weight markers, while 
the other four lanes (lanes 2, 3, 4 and 5) contain protein samples at different 











Figure 2.2: A representative example of SDS-PAGE analysis using hTDO. The first 





2.6.3 UV/Vis spectrophotometric analysis 
 
Spectrophotometric examination of a protein provides information about its purity 
and concentration. The peaks in the UV/visible spectra indicate the presence of 
different chromophores in the sample. While the peak at ~280 nm reflects the 
absorption of aromatic residues of the protein, peaks above 400 nm are due to 
absorption by the heme. The absorbance of the heme can be influenced by the status 
of the iron atom (ferric/ferrous), the presence of ligands (L-Trp, L-Trp + O2, O2, CO, 
CN-) and the source of the protein (human, rat). Using a Shimadzu UV-2101, PC 
spectrophotometer and quartz cuvette with a 1 cm path length, the purity of hIDO 
(black), hIDO2 (red) and hTDO (blue) have been monitored (fig. 2.3). The maximum 
absorbance of the Soret peak (405-409 nm), in combination with the Beer-Lambert 
law [A=clε where A = absorbance, c = enzyme concentration (molL-1), l = the path 
length of the sample (cm) and ε = extinction coefficient of the sample (Lmol-1cm-1)] 
may be used to calculate the concentration of the sample. Bradford and pyridyl 
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assays, which are described in sections 2.6.4 and 2.6.5, are used to work out % heme 
incorporation, and/or to work out the extinction coefficient for each protein. Once the 
coefficient is known UV/Vis spectrophotometric analysis is the best way to measure 
protein concentration. The extinction coefficients of hTDO, hIDO and hIDO2 are 
197,000 M-1cm-1, 172,000 M-1cm-1 and 126,000 M-1cm-1 correspondingly. 
 







































































Figure 2.3: The absorption spectra of (a) hIDO (black), (b) hIDO2 (red) and (c) 
hTDO (blue) after purified. The peak at ~280 nm reflects the total protein content, 
while the peak at ~405 nm (for hIDO and hIDO2) and ~408 nm (for hTDO) are the 
heme Soret peaks. Using the extinction coefficient of the Soret heme peak, the 
concentration of the functional protein (protein + heme) can be determined. 
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2.6.4 Bradford assay 
 
 
The concentrations of hTDO, hIDO and hIDO2 were determined using the Bradford 
assay (4). Coomassie Brilliant Blue G-250, the dye used, has an absorbance maximum 
at 465 nm. In the presence of a protein this maximum absorbance shifts to 595 nm 





Figure 2.4: Principle of the Bradford assay (4)  
 
Bovine serum albumin (BSA) solutions were used as protein standards. BSA 
solutions of known concentration were prepared, with absorbance values at 595 nm 
lying between 0 and 1.0 absorbance units. A standard curve was constructed by 
plotting A595 vs BSA concentration. The absorbance values of unknown 
concentrations of the proteins of interest were then compared with the standard 
curve, and the accurate protein concentrations were found using Microcal Origin 
software (fig. 2.5). Results were obtained in triplicate and at least two different 
protein concentrations were used in order to ensure the accuracy of the result. 
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 [Bovine serum albumin] mg/ml
 
 
Figure 2.5: Standard graph of bovine plasma albumin absorbance against 
concentration. The unknown sample of a given protein must have an absorbance 




2.6.5 Pyridine hemochrome assay 
 
Heme is an essential cofactor for TDOs and IDOs, and knowledge of the level of 
heme occupancy is important for activity measurements and in crystallographic 
studies. The level of incorporation of heme into enzymes used in this work was 
calculated via the pyridine hemochrome assay (5). In a quartz cuvette with a 1 cm 
path length, 20 µl of 5 µM protein was mixed with an equal volume of reagent A 
(Stock comprising 200 µl of 5 M NaOH, 2.5 ml pyridine, 2.3 ml H2O). A solution of 
Na2S2O4 (10 µl of 5 mg ml
-1) was immediately added and the UV/vis spectrum was 
recorded from 250-800 nm (Shimadzu UV-2101PC). The difference extinction 
coefficient ∆ε556-540 (22.1 mM
-1cm-1) was used for heme concentration determination. 
Results were obtained in triplicate. 
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2.7 Enzyme kinetics 
 
Kinetic analyses of hTDO, hIDO and hIDO2 were carried out by monitoring 
formation of N-formylkynurenine or N-formyl-kynurenine analogue over time. The 
formation of product was calculated using the change in absorbance at 321 nm, the 
wavelength where the molecule has the maximum absorbance. Each experiment was 
carried out either in 50 mM TrisHCl pH 8.0 (hTDO) or 100 mM KPi pH 6.5 (hIDO) 
or 100 mM KPi pH 7.5 (hIDO2). All the assay components were dissolved in the 
appropriate buffer at final concentrations of 20 mM ascorbate, 10 µM methylene 
blue and 10 µg/ml catalase.  Substrate (L-Trp and its analogues) and enzyme 
concentrations were varied depending on the combination of enzyme/substrate used. 
The experiments were carried out under aerobic conditions at 25 oC using a 
thermostatically controlled water bath. Data obtained were fitted to the Michaelis-




2.8 Determination of the pH dependence of IDO2 activity 
 
Determination of the optimum pH for enzymatic activity of hIDO2 was carried out 
by monitoring the formation of N-formyl-L-kynurenine over time in 100 mM 
potassium phosphate (KPi) buffer with the pH varied within the range 5.8 to 8.0 at 
increments of 0.2 pH units. The experiment was based on the protocol described in 










2.9 Microplate inhibition assay 
 
 The hTDO, hIDO and hIDO2 inhibition assays were carried out according to the 
method of Takikawa et al.(6) with minor modifications. The assays were carried out 
in a 96-well microplate with the components dissolved in either 100 mM KPi pH 
6.5(hTDO, hIDO) or 100 mM KPi pH 7.5 (hIDO2). Each well contained 200 µl of 
assay mixture. The reaction mixture was comprised of 20 µl of 0.4 M ascorbic acid, 
4 µl of 1 mM methylene blue, 4 µl of 10 mg/ml catalase, 20 µl L-tryptophan at final 
assay concentrations between 0- 800µM (hTDO), 0-45 µM (hIDO) and 0-8 mM 
(hIDO2), 2 µl of the inhibitor and 50 µl of the enzyme at final concentrations of 20 
nM (hTDO), 10 nM (hIDO) and 900 nM (hIDO2) and 100µl of KPi buffer. The 
reaction mixture was incubated at room temperature for either 15 min (hIDO), 20 
min (hTDO) or 30 min (hIDO2) and the reaction was terminated by adding 40 µl of 
trichloroacetic acid (30% w/v) into each well. Subsequently the microplate was 
transferred into an oven and incubated at 50 ºC for 30 min. The microplate was then 
centrifuged for 15 min at 4000 rpm and 125 µl of the supernatant transferred to a 
new microplate and mixed with equal volume of 4-dimethylaminobenzaldehyde 
(DMAB) in acetic acid (2% w/v). Finally, the absorbance was measured at 490 nm 
(fig 2.6), where the kynurenine-DMAB complex has a maximum (ε490 nm= 1500 M
-
1cm-1). The data was analyzed using Microcal Origin software. Calculation of the 
kynurenine-dimethylaminobenzaldehyde (DMAB) extinction coefficient was 
achieved using the above described method with minor modifications. The standard 
assay mixture (200 µl per well) contained 20 µl of 0.4 M ascorbic acid, 4 µl of 1 mM 
methylene blue, 4 µl of 10 mg/ml catalase, 20 µl L-kynurenine at final assay 
concentrations between 0-250 µM and 152 µl of the appropriate KPi buffer. The data 










Figure 2.6: The components of microplate inhibition assay and its principle. 
Kynurenine reacts with DMAB producing a schiff base, which absorbs at 490 nm.  
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2.10 Enzyme inhibition assay - cuvette method 
 
A cuvette-based inhibition assay was used as a control and as a means of confirming 
the accuracy of the microplate inhibition assay for TDO. To reduce further the 
chance of mistakes, two TDO inhibition results, obtained from the microplate assay, 
were compared with the corresponding cuvette outcomes. In the case of IDO, 
microplate results were compared with the corresponding published ones. The 
cuvette inhibition assay was carried out by monitoring formation of N-
formylkynurenine over time. All the reaction components, including substrate, were 
dissolved in 50 mM TrisHCl pH 8.0. The final concentrations of the assays reagents 
were 20 mM ascorbate, 10 µM methylene blue, 10 µg/ml catalase and 400 nM 
hTDO. Substrate and inhibitor concentrations were varied between 0-250 µM and 0-
8 µM respectively. The experiments were carried out under aerobic conditions at 25 
oC using a thermostatically controlled water bath. Data obtained were analyzed using 
Microcal Origin software. 
 
 
2.11 IDO double inhibitor assay 
 
The purpose of this IDO double inhibition assay is to assess the combined effect of 
the most potent NCI compounds with 1MT in IDO inhibition. The assay was carried 
out as described in section 2.9 (microplate inhibition assay) with minor 
modifications. 34 nM hIDO was incubated with 50, 100, 200 and 400 µM 1-MT for 
five minutes, in order to allow equilibration and binding of the inhibitor with the 
enzyme. Following this the IDO/1-MT mixture was added into a 96-well microplate 
and combined with 100 µM of NCI inhibitor (identified by microplate screening as 
described in section 2.9), dissolved in DMSO (1% DMSO final concentration). After 
addition of both 1-MT and NCI inhibitor to IDO, the reaction was initiated by adding 
100 µM mixture of L-Trp, ascorbate, methylene blue and catalase at concentrations 
mentioned in section 2.9. The reaction was allowed to proceed for 20 min and then 
terminated by adding 40 µl of trichloroacetic acid (30% w/v) into each well. 
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Subsequently the microplate was transferred into an oven and incubated at 50 ºC for 
30 min. The microplate was then centrifuged for 15 min at 4000 rpm and 125 µl of 
the supernatant transferred to a new microplate and mixed with equal volume of 4-
dimethylaminobenzaldehyde (DMAB) in acetic acid (2% w/v).  
 
2.12 Redox potentiometry 
 
 Optically transparent thin layer electrochemical (OTTLE) analysis is an 
electrochemical technique useful for the study of heme environment, of heme-
contained proteins, in the presence and absence of a particular substrate or inhibitor. 
The experiment was carried out under anaerobic conditions at 25 °C using a modified 
quartz EPR cell (7). Samples of hTDO, hIDO and hIDO2 were prepared in 0.1 M 
TrisHCl buffer, pH 7.5, 500 mM in KCl, 10 % glycerol (v/v) giving final enzyme 
concentrations from 40-60 µM. A number of mediators (2-hydroxy-1,4-
naphthoquinone (-145 mV vs. SHE), 5-hydroxy-1,4-naphthoquinone (-3 mV vs. 
SHE), phenazine ethosulfate (+55 mV vs. SHE), phenazine methosulfate (+82 mV 
vs. SHE), and 1,2-naphthoquinone (+135 mV vs. SHE) were also added in order to 
secure efficient reduction and re-oxidation of the enzyme (Table 2.2). 
Electrochemical titration of the enzymes was performed in the presence and absence 
of L-Trp and its analogues. All ligands were in excess, according to their solubility. 
All potentials measured were corrected relative to the SHE (standard hydrogen 
electrode) and data (wavelengths of Fe3+ and Fe2+ versus potentials) were fitted to 
Nernst equation (Microcal Origin) (fig. 2.7).  
 
Mediators Midpoint potential (mV) 
2-hydroxy-1,4-naphthoquinone -145 
5-hydroxy-1,4-naphthoquinone -3 
phenazine ethosulfate + 55 
phenazine methosulfate + 82 
1,2-naphthoquinone + 135 
 
Table 2.2: The mediators used in this study and their midpoint potentials. 
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Figure 2.7: a) Absorbance changes of hIDO in correlation with changes of the 







(1) Chauhan N., Thackray S.J., Rafice S.A., Eaton G., Lee M., Efimov I., Basran J., 
Jenkins P.R., Mowat C.G., Chapman S.K., and Raven E.L., Reassessment of the 
Reaction Mechanism in the Heme Dioxygenases, J. Am. Chem. Soc., 2009, 131, 
4186 – 4187 
 
(2) Rafice S.A., The oxidation of L-Tryptophan in Biology by Human Heme 
Dioxygenases, Thesis presented for the degree of Doctor of Philosophy, 2009, 
University of Leicester 
 
(3) Ball H.J., Sanchez-Perez A., Weiser S., Austin C.J.D., Astelbauer F., Miu J., 
McQuillan J.A., Stocker R., Jermiin L.S. and Hunt N.H., Characterization of an 
indoleamine 2,3-dioxygenase-like protein found in humans and mice, Gene, 2007, 
396, 203–213 
 
 (4) Bradford M.M., A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding, 
Analytical Biochemistry, 1976, 72, 248-54 
 
(5) Berry, E. A. and Trumpower B. L., Simultaneous determination of hemes a, b, 
and c from pyridine hemochrome spectra, Analytical Biochemistry, 1987, 161, 1-15 
 
(6) Takikawa O., Kuroiwa T., Yamazaki F., and Kido R., Mechanism of interferon-
gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human 
cells induced by interferon-gamma and evaluation of the enzyme-mediated 
tryptophan degradation in its anticellular activity, J. Biol. Chem.,1988, 263, 2041-8 
 
(7) Ost T. W. B., Clark J. P., Mowat C.G., Miles C.S., Walkinshaw M.D., Reid G.A., 
Chapman S.K. and Daff S., Oxygen Activation and Electron Transfer in 





Identification and characterisation of inhibitors of TDO and IDO 
 
 
3.1 Introduction  
 
This chapter describes efforts towards the development of TDO and IDO inhibitors. 
This involved screening of ~3000 potential TDO/IDO inhibitors and characterisation 
of the 67 most promising compounds. Among the molecules that have been tested 
there is a number of previously published inhibitors of either TDO or IDO, 
compounds that form part of the libraries of the National Cancer Institute, USA, 
isatin derivatives, a series of natural products, DNA bases, kynurenine-3-
monoxygenase (KMO) inhibitors, tryptophan derivatives and kynurenine/serotonin 




Figure 3.1: A brief summary of the ~3000 lead molecules that have been tested as 
inhibitors of TDO and IDO enzymes 
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Of the compounds tested as inhibitors of TDO/IDO, these can be divided into two 
main categories; i) The molecules that were obtained from the National Cancer 
Institute USA (~2800) (http://dtp.nci.nih.gov/repositories.html), and ii) the molecules 
that were ordered individually from several pharmaceutical and other companies 
(~210). A list of the individually ordered compounds can be found in Appendix A. In 
the case of the compounds obtained from the NCI, these have been further 
categorised into; i) approved oncology drug sets I and II, ii) natural product sets I and 
II, iii) mechanistic set and iv) diversity set II. Compounds in all sets were provided in 
96-well microplates, as 20 µl of a 10mM solution in 100% DMSO. The plates that 
contained these molecules were shipped frozen in dry ice. The approved oncology 
drug sets contain most current FDA-approved anticancer drugs. Further information 
about the purity of particular sets/compounds is given at the URL provided in section 
2.1. The natural product sets, composed of naturally occurring molecules, were 
selected according to their origin, purity (>90%), structural diversity and availability. 
The mechanistic diversity set, on the other hand, contains molecules that revealed 
inhibition potency against various human tumour cell lines. Last but not least is the 
diversity set, where the choice of the molecules was based on their structural 
diversity (hydrogen bond acceptor, hydrogen bond donor, positive charge, aromatic, 
hydrophobic, acid and base). Regarding the individually chosen molecules, selection 
was based on their structural similarities with either L-Trp, previously published 
inhibitors of IDO/TDO, or other molecules that were identified during this study as 
potent inhibitors of TDO/IDO. A number of natural occurring products such as 
vitamins are also included in the same list. Excluding isatin derivatives, which are 
discussed separately in Chapter 4, all the other groups of inhibitors (fig. 3.1) will be 









3.2 Microplate versus cuvette inhibition assay 
 
Prior to the characterization of the various TDO and IDO inhibitors, it was necessary 
to verify the accuracy of the microplate inhibition assay. For this reason TDO 
microplate results with mitomycin C and r493171 as inhibitors, and IDO microplate 
results with mitomycin C and 1-Me-L-Trp as inhibitors, were compared with the 
corresponding cuvette (fig. 3.2) and published results respectively (Table 3.1).  The 




Figure 3.2: Dixon plots of hTDO using mitomycin C (top) and r493171 (bottom) as 
inhibitors. For the cuvette assays, the concentrations of L-Trp used (all in µM) were: 
80 and 40 (black), 125 and 60 (red), 150 and 80 (blue), 200 and 125 (orange), 250 
and 150 (violet) for mitomycin and r493171 respectively. For the microplate assays, 
the concentrations of L-Trp used (all in µM) were: 300 and 300 (black), 350 and 350 
(red), 600 and 500 (blue), 700 and 700 (orange), 800 and 800 (violet) for mitomycin 
and r493171 respectively. 






































































As figure 3.2 shows, the cuvette inhibition assay findings were consistent with the 
corresponding microplate ones. While the cuvette assay for hTDO revealed 
inhibition constants of 2.52 ± 0.4 µM and 28.7 ± 2.3 µM for mitomycin C and 
r493171 respectively, the microplate assay provided inhibition constants of 2.86 ± 
0.03µM and 29.8 ± 2.4 µM. Similarly, IDO microplate inhibition assay results for 
mitomycin C and 1-Me-L-Trp, were confirmed by the equivalent published ones 
(Table 3.1).   
 













2.86 ± 0.03 
 
2.52 ± 0.4 
 
24.2 ± 1.2 
 








18.0 ± 3.4 
 




29.8 ± 2.4  
 






Table 3.1: Inhibition of TDO and IDO by mitomycin C, 1-Me-L-Trp and r493171. 
Accuracy of the microplate inhibition assay is verified by the cuvette assay and 




Figure 3.3: The TDO and IDO inhibitors used for verification of the microplate 
assay accuracy. 
Mitomycin C 1-Me-L-Trp r493171 
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3.3 Published TDO/IDO inhibitors  
 
The starting point in this work was to determine the specificity of published 
TDO/IDO inhibitors for either enzymes, this being a key step toward the 
development of specificity TDO/IDO inhibitors. Whereas this work examines the in 
vitro behaviour of hTDO and hIDO only, the term specificity refers to the selective 
inhibition of either hTDO or hIDO. Previous studies have thus far demonstrated that 
pyridyl compounds and 1-MT are the only specific inhibitors for TDO and IDO 
respectively (3), (4). While molecules such as naphthoquinones, ebselen and mitomycin 
C are published IDO inhibitors, their specificity against TDO has never been stated. 
Phenylimidazole and norharman, on the other hand, are known to inhibit both 
enzymes, and this is related with the ability of the two molecules to interact with the 
heme iron of TDO and IDO. For this reason, phenylimidazole and norharman will 
not be discussed further (5). The findings in regards to the most important TDO/IDO 
published inhibitors are summarised in table 3.2, and the aim of this section is to 















Table 3.2: Specificity of TDO and IDO inhibitors as categorised according to 


























In order to confirm the specificity of 1-MT against IDO and understand further the 
way that the molecule inhibits the enzyme, the kinetic, inhibition and redox 
responses of IDO and TDO against L-Trp, D-Trp and the two stereoisomers of 1-MT 
(1-Me-L-Trp and 1-Me-D-Trp) were examined. 
 
3.3.1.1 Turnover kinetics of D- and L-Trp and their 1-methylated derivatives  
 
Kinetic characterisation of IDO and TDO was carried out as described in section 2.7 
and the kinetic parameters for IDO and TDO with L-Trp, D-Trp, 1-Me-L-Trp and 1-
Me-D-Trp as substrate are presented in table 3.3. It was found that the 
physiologically-relevant substrate for these enzymes, L-Trp, is oxidised more 
efficiently by IDO (kcat/Km = 0.14 µM
-1s-1) than TDO (kcat/Km = 0.018 µM
-1s-1). In 
terms of substrate affinity, L-Trp has a 5-fold lower value of Km for IDO (20. 9 ± 4 
µM) than for TDO (Km = 112 ± 24 µM) while in terms of turnover rate, IDO has a 
kcat value around 1.5 times greater than TDO. 
 
 hIDO   hTDO 
Substrate kcat / Km 
(µM-1s-1)  
kcat (s
-1) Km (µM) kcat / Km 
(µM-1s-1)  
kcat (s
-1) Km (µM) 
L-Trp 0.142 3.0 ± 0. 2 
3.1 ± 0.2 (1) 
20. 9 ± 4 
15 ± 2 (1) 
0.018 2. 02 ± 0.04 
1.4 ± 0.019 (6) 
112 ± 24 
222 ± 15 (6) 
D-Trp 0.009 2. 7 ± 0. 3 
5.9 ± 0.3 (1) 
296 ± 19 
(2.6 ± 0.2) × 103 (1) 
0.0002 0. 47 ± 0. 04 
Not available 
2200 ± 324 
Not available 
1- Me-L-Trp 0.0009 0.062 ± 0.001 
0.064 ± 0.003 (1) 
70 ± 1 
62 ± 9 (1) 
- dnb dnb 
1-Me-D-Trp 0.0001 0. 095 ±0. 007 
Not available 
660 ± 43 
Not available 
- dnb dnb 
 
Table 3.3: Kinetic characteristics of hIDO and hTDO for L-Trp, D-Trp and their 1-
methylated derivatives, dnb = does not bind. For comparison, the published kinetic 
data for hIDO and hTDO, obtained from independent studies, are also presented. The 
data marked in blue were taken from ref. (1), while the data shown in green from ref. 
(6). 
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In the case of D-Trp turnover by TDO and IDO, some differences were apparent. In 
terms of kcat values, IDO retained its turnover ability at the same level as with L-Trp 
(3.0 ± 0.2 s-1 and 2.7 ± 0.3 s-1 for L-Trp and D-Trp respectively), while TDO turns 
over D-Trp approximately 4-fold more slowly (kcat = 2.02 ± 0.04 s
-1 for L-Trp and 
0.47 ± 0.04 s-1 for D-Trp). As expected, the affinities of both IDO and TDO for D-
Trp were lower, in contrast with L-Trp, demonstrating the enzymes’ selectivity for 
the L-isomer of tryptophan. The 8-fold difference in the catalytic efficiency of the 
two enzymes observed for L-Trp increased further for D-Trp, showing the distinct 
dissimilarities of the two enzymes in terms of substrate specificity. More specifically, 
D-Trp, is turned over more efficiently (45-fold) by IDO (kcat/Km = 0.009 µM
-1s-1) 
than TDO (kcat/Km = 0.0002 µM
-1s-1). The experimental results of TDO and IDO for 
L-Trp and D-Trp are presented in figure 3.4. 
Figure 3.4: TDO (a, c) and IDO (b, d) turnover assays for L-Trp (black curves) and 
D-Trp (red curves). 





















































Examination of turnover with the methylated derivatives of D- and L-Trp revealed 
no catalytic activity for TDO, something which is in agreement with the model and 
experiment results of Chauhan et al. (7). According to their proposition, a steric clash 
which occurs between a histidine residue in TDO (His55 for xcTDO or His76 for 
hTDO) and the methyl group of 1-MT prevents the binding of the molecule in the 
active site of the enzyme. In contrast, IDO oxidized both 1-Me-L-Trp and 1-Me-D-
Trp. The L-isomer of 1-MT binds to the enzyme fairly strongly (Km = 70 ± 1 µM), 
acting as a slow substrate. On the other hand, binding of 1-Me-D-Trp is less 
favourable (Km = 660 ± 43 µM). Similar to the findings for L-Trp and D-Trp, the kcat 
values for the 1-methyl derivatives of D- and L-Trp are comparable (0.062 ± 0.001 s-
1 and 0.095 ± 0.007 s-1 for 1-Me-L-Trp and 1-Me-D-Trp respectively). The turnover 
graphs of IDO for 1-Me-L-Trp and 1-Me-D-Trp are illustrated below (fig. 3.5) 
 
Figure 3.5: IDO turnover for 1-Me-L-Trp (a) and 1-Me-D-Trp (b) 
 
 
3.3.1.2 Inhibition of hIDO and hTDO by L-Trp, D-Trp, 1-Me-L-Trp and 1-Me-
D-Trp  
 
Although IDO is a monomeric protein, the inhibition data indicated that substrate 
inhibition occurs at L-Trp concentrations ≥50 µM (Table 3.4). According to recent 
findings this phenomenon is not related with an allosteric effect (a secondary binding 
site for L-Trp) but it has to do with the order that L-Trp and O2 bind at the active site 
of the enzyme (8). At low substrate concentrations, O2 binds first allowing the 




























formation of a ferric superoxide intermediate. However, at high substrate 
concentrations (≥50 µM) the order is reversed affecting the formation of ferric 
superoxide intermediate and therefore the catalytic ability of IDO. Despite the fact 
that TDO is a tetrameric protein with two L-Trp binding sites per monomer, 
inhibition of the enzyme by L-Trp was not observed. As figure 3.6 shows, D-Trp 
inhibits both enzymes but with different affinities. 
 














543 ± 35 
 














Table 3.4: Inhibition of hIDO and hTDO in the presence of D-Trp, 1-Me-L-Trp and 
1-Me-D-Trp. ni = no inhibition, dnb = does not bind. 
 
 
Figure 3.6: Dixon plots of TDO (a) and IDO (b) using D-Trp as inhibitor. The 
concentrations of L-Trp used (all in µM) were: 300 and 25 (black), 400 and 30 (red), 






































While IDO displayed a Ki value of 543 ± 35 µM, TDO inhibition is significantly 
weaker, yielding a Ki value of 5030 ± 60 µM. These Ki values are broadly in line 
with the difference between the D-Trp Km values given for each enzyme in table 3.3.  
Study of the N1-methylated derivatives of L-Trp and D-Trp revealed no inhibition of 
TDO. This observation is in line with their lack of binding to TDO as explained 
above. However, IDO enzymatic activity was found to be affected by the presence of 
1-Me-L-Trp, which was found to inhibit the enzyme with a Ki value of 18.0 ± 3.4 
µM. A Dixon plot for inhibition of IDO by 1-Me-L-Trp is given in figure 3.7. While 
1-Me-L-Trp is a good inhibitor of IDO, 1-Me-D-Trp did not affect the activity of the 











Figure 3.7: Dixon plot of IDO using 1-Me-L-Trp as inhibitor. The concentrations of 




3.3.1.3 Electrochemical analysis of IDO and TDO 
 
Electrochemical analysis of TDO and IDO was carried out as described in section 
2.12. The electrochemical behaviour of IDO and TDO was examined in the absence 
and presence of L-Trp, D-Trp, 1-Me-L-Trp and 1-Me-D-Trp and the results are 
presented in table 3.5. For both IDO and TDO, the presence of L-Trp caused a shift 
in the heme midpoint potentials of +38 mV and +129 mV respectively (fig. 3.8), 

















which is presumed to be indicative of conformational changes occurring at the active 
sites of the two enzymes upon L-Trp binding. In the case of TDO this has been 
discussed as supporting the idea that TDO is an induced-fit enzyme (9). In the 
presence of D-Trp, however, only TDO shows a potential shift (+77 mV relative to 
the substrate-free enzyme), while the 1-methylated derivatives cause no shift in 
potential in IDO, and do not bind to TDO at all. It is interesting to note that despite 
the fact that 1-Me-L-Trp is a relatively good inhibitor of IDO there is little effect 
upon the heme potential upon binding, raising questions about the nature of ligand 





Em  hIDO (mV vs. SHE) 
 





- 54 ± 8 
 




-16 ± 6 
 




-57 ± 12 
 














Table 3.5: Reduction potentials of hIDO and hTDO as free enzyme or saturated with 
L-Trp, D-Trp, 1-Me-L-Trp and 1-Me-D-Trp.  
 
 
Figure 3.8: Reduction potentials of (a) hTDO and (b) hIDO as free enzymes (black 
curves) and in the presence of L-Trp (red curves).



















































3.3.2 Naphthoquinone-based inhibitors 
 
 
The naphthoquinone-based inhibitors are a family of inhibitors with important 
impact in IDO inhibition (10). Naphthoquinone-based drugs are well studied and used 
for treatment of various types of cancer. A recent FDA-approved drug with a 
naphthoquinone moiety is mitomycin C, which is also an inhibitor of IDO and will 
be discussed below. In addition to their proved pharmaceutical usefulness, 
naphthoquinone-like structures are also found in a number of natural occurring 
products such as vitamin K.   
 According to Kumar et al. (10), this class of molecules inhibits IDO activity 
with satisfactory inhibition potency, but without clarifying whether they are also 
inhibitors for TDO. The findings of Kumar and co-workers supported the notion that 
the essential moiety for IDO inhibition is either 1,2-naphthoquinone or 1,4-
naphthoquinone, reporting at the same time that the equivalent benzoquinones are 
inactive (fig. 3.9).  
 
 
Figure 3.9: Benzoquinones and naphthoquinones. A previous study has suggested 
that naphthoquinone moiety is the smallest active IDO inhibitor (10). However, it is 
demonstrated here that benzoquinones are also active TDO inhibitors.  
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From figure 3.10 it can be seen that both 1,4-benzoquinone (blue curve) and 
tetrachloro-1,2-benzoquinone (red curve) are inhibitors of TDO and IDO, thus 
showing that benzoquinone is the smallest active moiety that inhibits both enzymes 
(fig. 3.10). Testing various naphthoquinone-like molecules (14 in total), it was 
verified that this group of compounds are inhibitors of both TDO and IDO. 
Information about the structures of the naphthoquinone-based inhibitors that were 
used can be found in the inhibitors list (Appendix A, numbers 72-84 and 86 in the 
list). While reduction of 1,4-naphthoquinone to 1,4-dihydroxynaphthalene (the 
reduced form of 1,4-naphthoquinone contains hydroxyl groups at 1 and 4 positions of 
the aromatic ring) did not affect the inhibition potency of the molecule, insertion of 
an electron-withdrawing carboxylic acid group at the 2 position of the hydroquinone 
form caused the loss of inhibition activity in both TDO and IDO.  
 
 
Figure 3.10: Inhibition of a) hTDO and b) hIDO by benzoquinones. The control 
curve (L-Trp) is shown in black while the reactions inhibited by 1,4-benzoquinone 
and tetrachloro-1,2-benzoquinone are shown in blue and red respectively. Both 



































































Ebselen is another inhibitor of IDO, characterized as non-specific because of its 
ability to form Se-S bonds with the side chains of cysteine residues (11). Due to this 
mode of action it is possible that ebselen could be also considered as an inhibitor of 
TDO (in contrast with IDO, which contains 8 cysteine residues, TDO has only 3). 
Indeed, as figure 3.11 shows, ebselen inhibits both TDO and IDO. However, the 
potency of this molecule against the two enzymes differs, being noticeably stronger 
as an inhibitor for IDO than it is for TDO.  
 While it might be said that ebselen’s proposed mode of inhibition may render 
it completely non-specific, the conclusions revealed from ebselen’s action are highly 
interesting. Terentis and co-workers showed that the action of this inhibitor implies 
structural modification of IDO, something which in turn affects the active site of the 
enzyme and its activity (11). Herein it is shown that the effect of 400 µM ebselen, in 
inhibition of IDO and TDO, is significantly different. Mutation of TDO cysteine 
residues could provide important information about the cysteines’ implication on 
enzyme’s stability/activity.  
 
 
Figure 3.11: Inhibition of a) hTDO and b) hIDO by ebselen. The control curve (L-
Trp) is shown in black while the ebselen-inhibited reaction is shown in red. The final 
concentration of ebselen was 400µM. 
 
 





















































3.3.4 Mitomycin C 
 
 
In 2009, Lou and co-workers published a paper in which mitomycin C was reported 
as inhibitor of IDO (1). Table 3.1 demonstrates that mitomycin C inhibits TDO as 
well, with an inhibition constant of 2.86 ± 0.03µM. Comparison between the two 
enzymes showed that mitomycin C is more potent TDO inhibitor than IDO. 
Considering the fact that mitomycin C is an approved oncology drug, its inhibition 






Findings published in the 1990s characterised this family of molecules as inhibitors 
for TDO with inhibition constants in the nanomolar range (12), (13). In vitro studies 
now reveal that the pyridyl molecules inhibit both TDO and IDO enzymes. The 
inhibition activity of 2-pyridyl against the two enzymes is shown in figure 3.12. In 
addition, the 3-pyridyl and 4-pyridyl compounds were also tested with similar 
outcomes (no specificity against TDO). The structures of these molecules can be 
found in chapter 1, section 1.17. 
 
Figure 3.12: Inhibition of a) hTDO and b) hIDO by 2-pyridyl (400 µM). These 
findings clarify that pyridyl compounds show no specificity against TDO. The 
control curve (non-inhibited reaction) is shown in black while the reaction that is 
inhibited by 2-pyridyl is presented in red. 
 






















































3.4 National Cancer Institute library compounds as TDO and IDO inhibitors 
 
Plate screening of ~2800 potential inhibitor compounds obtained from the National 
Cancer Institute indicated that 7 of these compounds (fig. 3.13) displayed promise as 
inhibitors of both TDO and IDO, as evidenced by inhibition constants either in the 
nanomolar or low micromolar range (Table 3.6). The Dixon plots for each of these 
potent lead molecules are shown in figure 3.14. Interestingly, of these seven 
inhibitors, six have been identified to have cytotoxic action against several types of 
tumour cells (NCI data). NSC 26326, known as β-lapachone, is a natural occurring 
quinone that can be isolated from the lapacho tree (Tabebuia avellanedae). A series 
of studies (14-19) have shown that NSC 26326 affects the survival rate of cancer cells 
such as pancreatic, breast, colon, retinoblastoma, leukaemia and non-small-cell lung 
cancer. Of all the reported inhibitors herein, NSC 26326 is the strongest inhibitor of 
both IDO and TDO with inhibition constants of 97 ± 14 nM and 30-70 nM 
respectively. Like NSC 26326, NSC 36398 is another natural product that belongs to 
the class of flavonoids. Among the several flavonoids that have been examined 
(Appendix A), NSC 36398 is the most potent inhibitor of TDO with a Ki of 16.3 ± 
3.8 µM. In contrast with TDO, IDO was not found to be inhibited by NSC 36398 at 
concentrations up to 100 µM. The low toxicity of flavonoids in combination with 
their previously reported anticancer function makes NSC 36398 an attractive lead in 
cancer therapy (20). NSC 267461, or nanomycin A, is a naphthoquinone based 
inhibitor, inhibiting IDO and TDO with Ki values of 950 ± 270 nM and 360 ± 30 nM 
respectively. NSC 267461 is active in 59 tumour cell lines, killing several types of 
cancer cells (21). 
NSC 111041 also inhibits TDO and IDO with inhibition constants of 1.1 ± 0.3 µM 
and 4.3 ± 0.9 µM respectively. Examination of this compound revealed activity 
against colon and breast tumour cell lines (21). NSC 255109 (17-
aminodemethoxygeldanamycin) is a good inhibitor for both TDO and IDO, with 
inhibition constants in the nanomolar range. For TDO, Ki was found to be 600 ± 70 
nM and for IDO it was 1.4 ± 0.5 µM. Tests on tumour cell lines showed that NSC 
255109 is active in 65 different cell lines and the types of cancer cells that this 
 83 
compound is effective on are given in table 3.6 (21). NSC 261726, or 3-deazaguanine, 
is an inhibitor with activity in the lower micromolar range (Ki values of 5.6 ± 0.4 µM 
and 21.4 ± 2.4 µM for TDO and IDO respectively). NSC 261726 was found to be 
active in colon and leukaemia tumour cell lines, something which increases the 
interest in this compound (21). Despite the structural similarities between NSC 
261726 and guanine, the latter showed no inhibitory activity on either TDO or IDO. 
Indeed, none of the heterocyclic nucleic acid bases indicated potential inhibition 
activity for IDO or TDO. Finally, among the compounds identified by screening is 







Figure 3.13: Structures of the seven NCI inhibitors that inhibit TDO and IDO with 
high affinity. Important to note is that these molecules are also active in various 























97 ± 14 nM 
 
Pancreatic cancer, breast cancer, 
colon cancer, retinoblastoma, 






























Non-small cell lung cancer, 
melanoma cancer, prostate cancer, 
central nervous system cancer, small 
cell lung cancer, colon cancer, breast 








1.1 ± 0.3 µM 
 
 
4.3 ± 0.9 µM 
 
 












1.4 ± 0.5 µM 
 
Non-small cell lung cancer, 
melanoma cancer, prostate cancer, 
central nervous system cancer, colon 
cancer, breast cancer, ovarian 







5.6 ± 0.4 µM 
 
 
21.4 ± 2.4 µM 
 
 
















24.2 ± 1.2 µM 
 
Non-small cell lung cancer, 
melanoma cancer, prostate cancer, 
central nervous system cancer, small 
cell lung cancer, colon cancer, breast 




Table 3.6: Inhibition constants of seven NCI inhibitors (measured in this work) 
against TDO and IDO. Information includes Ki values and which tumour cell lines 
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Figure 3.14: Dixon plots of hTDO (left column) and hIDO (right column) using a) 
NSC 26326, b) NSC 36398, c) NSC 111041, d) NSC 255109, e) NSC 261726, f) 
NSC 267461 and g) mitomycin C as inhibitors. (a) NSC 26326. Substrate 
concentrations used (all µM) were: TDO, 300 (black), 500 (red), 600 (blue), 700 
(orange), 800 (violet); IDO, 15 (black), 25 (red), 30 (blue), 40 (orange), 45 (violet). 
(b) NSC 36398. Substrate concentrations (µM) were 300 (black), 350 (red), 400 
(blue), 500 (orange), 600 (violet). (c) NSC 111041. Substrate concentrations used (all 
µM) were: TDO, 300 (black), 350 (red), 400 (blue), 600 (orange), 800 (violet); IDO, 
15 (black), 20 (red), 25 (blue), 30 (orange), 45 (violet). (d) NSC 255109. Substrate 
concentrations used (all µM) were: TDO, 300 (black), 500 (red), 600 (blue), 700 
(orange), 800 (violet); IDO, 15 (black), 30 (red), 35 (blue), 40 (orange), 45 (violet). 
(e) NSC 261726. Substrate concentrations used (all µM) were: TDO, 350 (black), 
400 (red), 500 (blue), 600 (orange), 800 (violet); IDO, 15 (black), 25 (red), 30 (blue), 
40 (orange), 45 (violet). (f) NSC 267461. Substrate concentrations used (all µM) 
were: TDO, 300 (black), 400 (red), 500 (blue), 600 (orange), 800 (violet); IDO, 15 
(black), 20 (red), 25 (blue), 35 (orange), 45 (violet). (g) Mitomycin C. Substrate 
concentrations used (all µM) were: TDO, 300 (black), 350 (red), 600 (blue), 700 
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3.4.1 Combination of 1-MT with the seven antitumour agents for hIDO 
inhibition  
 
In this work we have combined 1-MT with the 7 NCI inhibitors that are mentioned 
above, in order to investigate the effect of combinations on inhibition of IDO. 
Having in mind the antitumour properties of 1-MT in combination with the 
assumption that the molecule has similar to L-Trp orientation in the active site of 
IDO (section 1.12), we combined 1-MT with the seven chemotherapeutic agents in 
order to achieve a more effective inhibition of IDO.  The results obtained from this 
trial are shown in figure 3.15. From the figure it can be seen that consistent results 
are obtained in each of the seven individual assay plates in the presence of only 1-
MT as an inhibitor. At 50 µM 1-MT around 88-97% of uninhibited activity is 
observed, dropping to ~55-60% of uninhibited activity at 400 µM 1-MT. In the 
presence of 100 µM NSC 26326 (IDO Ki = 97 ± 14 nM), it can be seen from figure 
3.15 that there is almost complete inhibition of the enzyme, with only ~2 % of the 
inhibitor-free activity being observed. In this respect, the strength of inhibition of 
NSC 26326 means that further addition of increasing amounts of 1-MT has little 
appreciable effect on the overall inhibition observed. This type of response is also 
observed in the presence of NSC 267461 (IDO Ki = 950 ± 270 nM), with addition of 
100 µM of the inhibitor leading to a loss of ~97% of the inhibitor-free activity, and 
the additional presence of 1-MT having little additional effect. Similar responses are 
also seen with NSC 111041 (IDO Ki = 4.3 ± 0.9 µM) and, to a lesser extent, NSC 
255109 (IDO Ki = 1.4 ± 0.5 µM). In the case of NSC 111041, the presence of the 
inhibitor at 100 µM leads to loss of ~93% of IDO activity with 1-MT addition at 400 
µM raising this level to ~96% inhibition. For NSC 255109 the effect is slightly less 
marked, with its presence at 100 µM resulting in around 90% inhibition of enzyme 
activity, while concomitant addition of increasing amounts of 1-MT causes a steady 
decrease in activity to a maximum of 96% inhibition at 400 µM 1-MT.  
The remaining NCI compounds have less dramatic effects on IDO activity at 100 
µM. The presence of 100 µM NSC 36398 (Ki > 100 µM) leads to retention of 
approximately 85% of uninhibited IDO activity. Combination of this inhibitor with 
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varying 1-MT concentrations revealed a consistent decrease in the enzyme’s activity 
to around 80-85% of the activity in the presence of the same 1-MT concentration but 
in the absence of the NCI compound. With 100 µM NSC 261726 present (IDO Ki = 
21.4 ± 2.4 µM) there is a decrease in enzyme activity to around 27% of the 
uninhibited value, while addition of 1-MT in tandem with NSC 261726 causes 
further inhibition by the same proportion as observed with increasing amounts of 1-
MT but in the absence of the NCI compound (fig. 3.15). Finally, mitomycin C is 
known to inhibit IDO (section 1.12) with a Ki value of 24.2 ± 1.2 µM. Its presence in 
the assay at 100 µM causes activity to fall to ~36% of full activity, with additional 
inhibition by increasing concentrations of 1-MT following the same trend as 
observed for NSC 36398 and NSC 261726.  
From these results it can be seen that the effect of using combinations of 1-MT with 
the newly-identified NCI compound inhibitors is simply additive, with the dominant 




















































































































































































































Figures 3.15: Combination of 1-MT with NCI inhibitors for inhibition of IDO. a) 
NSC 26326, b) NSC 36398, c) NSC 267461, d) NSC 111041, e) NSC 255109, f) 
NSC 261726 and g) mitomycin C. The black, blue, pink and navy blue columns 
represent 50 µM, 100 µM, 200 µM and 400 µM of 1-MT without and with 100 µM 
NCI inhibitors. In dark cyan is the NCI inhibitor at the same concentration as it is in 



































































































































































3.5 Natural products 
 
 
Whereas inhibition of IDO by natural products is well documented (see section 
1.12), little is known about their action on TDO. This section examines the inhibition 
effect of various natural products on both TDO and IDO. Screening indicated several 
types of natural products (vitamin K1, flavones, NSC 100445 and riboflavin) with 
potential inhibition action against either TDO or IDO or both (fig. 3.16). The most 
potent flavone derivative inhibitor (NSC 36398) has already been discussed in 





Figure 3.16: The structures of some natural products that have been identified herein 







3.5.1 Vitamin K1 
 
 
Vitamin K1 is a naphthoquinone-based, fat-soluble natural product with inhibition 
activity against both enzymes (fig. 3.17). Because of its poor solubility in water, 
vitamin K1 is not a useful lead inhibitor for either TDO or IDO and therefore its 
study is terminated here. 
 
Figure 3.17: Demonstration of (a) TDO inhibition and (b) IDO inhibition by vitamin 
K1(400 µM final concentration). Control = black, vitamin K1= red. 
 
3.5.2 NSC 100445 
 
 
NSC 100445 is a weak inhibitor of TDO with negligible effect on IDO (fig. 3.18). 
Further understanding of its action demands development of NSC 100445 
derivatives, something which is not within the aims of the current project. 
 
Figure 3.18: Inhibition of (a) TDO and (b) IDO by NSC 100445 (400 µM final 
concentration). Control = black, NSC 100445 = red. 












































































































In contrast with vitamin K1, riboflavin which is also known as vitamin B2, is a water 
soluble natural product. Riboflavin was found to inhibit TDO and IDO enzymes with 
inhibition constants of 5.85 ± 0.47 µM and 10.3 ± 0.77 µM respectively (fig. 3.19).  
 
Figure 3.19: Dixon plots for inhibition of a) TDO and b) IDO by riboflavin. 
Substrate concentrations used (all µM) were: TDO, 300 (black), 350 (red), 400 
(blue), 500 (orange), 600 (violet); IDO, 15 (black), 25 (red), 30 (blue), 40 (orange), 
45 (violet).   
 
Important to note is that riboflavin is the central component of flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN), the structures of which are 
presented in figure 3.20. FAD and FMN are co-factors of various proteins and 
implicated in a series of metabolic pathways. FAD is a co-factor of kynurenine-3-
monoxygenase (KMO), an enzyme that participates in tryptophan metabolism, 
transforming kynurenine into 3-hydroxykynurenine. 
 
 
Figure 3.20: Structures of riboflavin, FMN and FAD 



































With this in mind, FMN and FAD were also tested as inhibitors of TDO and IDO and 
the results were compared with riboflavin findings (fig. 3.21). Interestingly, both 
FMN and FAD were found to inhibit TDO and IDO, but with lower potency than 
riboflavin. 
 
Figure 3.21: Inhibition of a) TDO and b) IDO by FAD (red), FMN (blue) and 
riboflavin (green). All three were used at 400 µM final concentration. 
 
 
For a better understanding of the way that riboflavin inhibits the two enzymes, 
lumiflavin was also investigated as an inhibitor. Replacement of riboflavin’s poly-
hydroxyl tail by a methyl group gives lumiflavin. Lumiflavin is a less effective 
inhibitor than riboflavin (fig. 3.22), something which indicates implication of the 
poly-hydroxyl tail in the binding of the molecule. 
 
Figure 3.22: Inhibition of a) TDO and b) IDO by lumiflavin (dark yellow) and 
riboflavin (orange). Both molecules were used at 400 µM final concentration. 









































































































3.6 Kynurenine pathway metabolites 
 
 
As potential inhibitors of TDO and IDO, it is logical to also investigate the 
kynurenine pathway metabolites. In total, six kynurenine pathway metabolites were 
tested (kynurenine, 3-hydroxykynurenine, kynurenic acid, 3-hydroxyanthranilic acid, 
anthranilic acid and NAD) but only one, 3-hydroxyanthranilic acid, revealed 
inhibition activity against both enzymes (fig. 3.23). The well-reported cytotoxic 
properties of 3-hydroxyanthranilic acid (section 1.3.2) discourage any trials of using 
this molecule for developing inhibitors for TDO and IDO. 
 
     Figure 3.23: Inhibition of a) TDO and b) IDO by 3-hydroxyanthranilic acid (red). 





3.7 Other potential inhibitors 
 
 
As the inhibitor list shows (Appendix A), the search for TDO/IDO inhibitors was not 
limited to the categories that are mentioned above. DNA/RNA bases, tryptophan and 
indole derivatives, and KMO inhibitors are among the molecules that have been also 
tested. However, none of these compounds indicated potential inhibition activity 
against either TDO or IDO. 
 
 






















































The starting point of this chapter was the study of the various published inhibitors. 
The conclusions from this trial are illustrated in table 3.7. 1-methyltryptophan is the 
only specific inhibitor for IDO while pyridyls showed no specificity against TDO. 
All the other inhibitors, naphthoquinones, ebselen, mitomycin C, phenylimidazole 































Table 3.7: Allocation of the various TDO and IDO inhibitors as specific for either 
enzyme or not specific according to the published results (“before”) and after this 






















IDO and TDO 










Inhibition, redox and turnover examination of hIDO and hTDO clearly points to 1-
Me-L-Trp being the only inhibitor specific for hIDO. Neither 1-Me-L-Trp nor 1-Me-
D-Trp inhibits hTDO. The specificity of hIDO for the L-isomer of 1-MT is 
illustrated by the turnover findings, which show that binding of 1-Me-D-Trp to IDO 
is unfavourable and therefore no inhibition is observed. The fairly high affinity of 1-
Me-L-Trp, in combination with the poor turnover rate makes it (thus far) the only 
possible inhibitor for IDO, in vitro.  
Despite this, phase I clinical trials for study of 1-Me-D-Trp as inhibitor of IDO are 
currently in progress (http://clinicaltrials.gov/ct2/show/NCT00617422). 1-Me-D-Trp 
is an ineffective in vitro inhibitor of IDO and the potential inhibition activity that this 
molecule may have in cancer cells could be related with inhibition of other than 
hIDO protein(s).  
 While many inhibitors of IDO have been identified and published, thus far 
none of them possess the properties of 1-MT. Because of its low toxicity and 
specificity for IDO, 1-MT has been studied extensively, but without any significant 
outcome, mainly because of its competitive type of inhibition. Nevertheless, 
combination of 1-MT with the seven chemotherapeutic agents, reported above, 
provides a new approach towards the potential use of 1-MT as an anticancer drug. β-
Lapachone (NSC 26326), a promising anticancer agent, revealed synergistic action 
with 1-MT, causing further inhibition of hIDO. β-Lapachone is known for its 
selectivity in killing several types of cancer cells while leaving normal cells intact 
(22), (23).  Its action is highly depended on the expression of NAD(P)H: quinone 
oxidoreductase-1 (NQO1), an enzyme that catalyses reduction of quinones to 
hydroquinones. Various types of cancers, and in particular pancreatic cancer, 
overexpress NQO1 by more than 10-fold in comparison with normal cells (24). 
Reduction of β-lapachone by NQO1 increases the amount of reactive oxygen species 
(ROS), causing apoptosis in cancer cells. Recent findings show that β-lapachone, 
under optimal conditions, causes neither toxicity nor haemolytic anemia to normal 
tissue (24). In addition, it shows a synergistic effect with radiation, something which 
further increases the interest in this molecule (25). In contrast with β-lapachone, the 
flavone-derivative NSC 36398, is not an ideal inhibitor for IDO. However, the 
molecule demonstrated a preference for TDO, inhibiting the enzyme in the low 
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micromolar range (Ki = 16.3 ± 3.8 µM). After testing numerous TDO and IDO 
inhibitors (~3000 compounds), NSC 36398 is the only compound that reveals 
selectivity for TDO. Considering flavones’ low toxicity, NSC 36398 may well be a 
useful inhibitor for TDO. NSC 267461 or nanaomycin A is reported as an inhibitor 
of DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), inducing  DNA 
demethylation (26). Although DNA methylation is essential during embryonic 
development, abnormal methylation of DNA silences many tumour suppressor 
genes, leading to cancer. The combined effect of nanaomycin A and 1-MT, allied to 
nanaomycin’s ability to inhibit DNMT3B might increase the effectiveness of 1-MT 
in vivo, providing new insights in cancer treatment. NSC 255109 is a benzoquinone-
based antibiotic and analogue of geldanamycin. Geldanamycin is a molecule with 
antitumour activity through its competitive binding to the ATP binding pocket of 
heat shock protein 90 (Hsp90) (27). Because of geldanamycin’s hepatotoxicity a 
number of analogues were developed by substitution at the 17-position of the 
maternal molecule. One of these is NSC 255109, a strong inhibitor of TDO and IDO. 
Phase I pharmacokinetic and pharmacodynamic studies of 17-allylamino-17-
demethoxygeldanamycin (17-AAG), another geldanamycin analogue, showed that 
these derivatives can be safely administered in cancer patients, retaining their 
antitumour activity (27), (28). These findings in combination with the strong inhibition 
activity of NSC 255109 for IDO and its synergistic action with 1-MT indicate the 
possibility of combination therapy with 1-MT.  
 NSC 261726 (3-deazaguanine) is a purine analog found to have antitumour 
activity on leukemia and colon cancer cells (21). Because of its structural similarity 
with guanine, 3-deazaguanine is likely to suppress DNA synthesis. 3-deazaguanine 
can inhibit both TDO and IDO in the micromolar range and act synergistically with 
1-MT for optimization of IDO inhibition. Binding of 3-deazaguanine is independent 
of L-Trp concentration and therefore combination of 3-deazaguanine with 1-MT can 
cause strong inhibition of IDO in the low micromolar range. Like 3-deazaguanine, 
mitomycin C can inhibit IDO in the presence of 1-MT. Bearing in mind that the list 
of TDO inhibitors is far from lengthy, these seven NCI inhibitors may provide a 
means of finding strong inhibitors for the enzyme. Their combination with 1-MT for 
inhibition of IDO, in combination with the good inhibition activity that these 
 99 
inhibitors have on TDO, provides new insights into usage of these. Studying these 
inhibitors, it became apparent that their ability to kill cancer cells is related with 
influence on either two proteins (β-lapachone) or a protein and DNA (mitomycin C). 
Their action as inhibitors of TDO and IDO is a new development and in combination 
with the proven negative involvement of these proteins in cancer, it could be 
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Isatins as inhibitors for TDO and IDO 
 
 
4.1 Introduction  
 
 
In the light of recent findings implicating TDO in cancer survival and migration (1), 
interest in inhibition of the tryptophan catabolic enzymes TDO and IDO is 
reinforced. In the search for new TDO/IDO inhibitors isatin was an attractive target, 
not only because of the tryptophan-like structure but also because of the established 
biological and pharmacological role of isatin derivatives as oncology drugs 
(http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm10858
3.htm). In addition to their anticancer activity, isatin derivatives have several other 
applications as, for example, anticonvulsants, antimicrobials and antidepressants 
drugs (2). 
  Isatin or 1H-indole-2,3-dione is an orange-red crystalline compound, which 
was discovered in the 19th century as a result of indigo oxidation (fig. 4.1)  and it is 
found in plants, fruits, animals and humans (3). In humans, it is proposed that isatin is 
an endogenous product of tryptophan oxidation, occurring in the liver after the 
consumption of tryptophan-rich food (4). 
 
 
Figure 4.1: Production of isatin from indigo oxidation. Oxidation of indigo causes 
breakdown of C=C bond producing two isatin molecules.  
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This chapter describes the inhibitory effects of isatin and a number of modified 
isatins on both TDO and IDO. The structural modifications were chosen carefully in 
order to obtain information about the functional groups of isatin, such as the two 
carbonyl groups, the nitrogen atom of the pyrrolidine ring, and the benzene and 
pyrrolidine rings (fig. 4.2).  
In addition to this, the effect of combination of 1-MT and isatins on IDO inhibition 
was investigated (method described in section 2.11). The findings reveal these 
compounds to be a new class of TDO and IDO inhibitors with inhibition constants in 









4.2 N-1 methylation of isatin  
 
Isatin is a weak inhibitor of TDO/IDO enzymes with inhibition constants of 132 ± 4 
µM and 89 ± 6 µM for TDO and IDO respectively (Table 4.1). Bearing in mind the 
specificity of 1-methyltryptophan (1-MT) as an IDO inhibitor only, the effect of the 
N1-methylation of isatin was investigated. The structure of 1-methylisatin is shown 
in figure 4.3. Interestingly, methylation of isatin caused a modest decrease in affinity 
towards both enzymes, shifting the inhibition constant from 132 ± 4 µM to 170 ± 13 
µM for TDO and from 89 ± 6 µM to 111 ± 23 µM for IDO (Τable 4.1).  
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4.3 Halogenation of isatin 
 
Given the electron-withdrawing properties of halogens attached to aromatic rings, the 
inhibition potential of monochlorinated and dichlorinated isatins was investigated 
(fig. 4.3). Dixon plots for isatin and its chlorinated derivatives are illustrated in figure 
4.4 while their inhibition constants are shown in table 4.1. Chlorination of isatin at 
the 5-position is found to increase isatin’s inhibition effectiveness by 12-fold and 6-
fold for TDO and IDO, with Ki values of 10.5 ± 0.4 µM and 15.2 ± 1 µM 
respectively. Movement of the chlorine atom from the 5-position to the 7-position of 
the benzene ring had a negligible effect on both enzymes, resulting in inhibition 









Dichlorination on the other hand, had a noticeable impact on TDO inhibition while 
leaving IDO fairly unaffected. In the presence of 4,7-dichloroisatin TDO inhibition 
was barely affected in comparison with the monochlorinated isatins, but the Ki was 
around 10-fold lower for 5,7-dichloroisatin in comparison with either of the 
monochlorinated isatins (0.8 ± 0.2 µM, Τable 4.1). In the case of IDO, both 4,7-
dichloroisatin and 5,7-dichloroisatin had similar impact on inhibition, offering minor 
optimization of the inhibition constant in contrast with the monochlorinated isatins. 
The position of chlorine atoms in the benzene ring of isatin proved to be important 
for the effectiveness of the potential inhibitor particular for TDO, something that 
cannot be said for IDO. 
 
 




132 ± 4 µM 
 




170 ± 13 µM 
 




10.5 ± 0.4 µM 
 




9.3 ± 0.4 µM 
 




3.8 ± 0.04 µM 
 




0.8 ± 0.2 µM 
 
5.9 ± 0.4 µM 
             
Table 4.1: Inhibition of hTDO and hIDO by isatin, 1-methylisatin and chlorinated 
derivatives of isatin. The Ki values of isatin and its derivatives were measured as 

























































































































































Figure 4.4: Dixon plots of hTDO (left column) and hIDO (right column) using a) 
isatin, b) 1-methylisatin, c) 5-chloroisatin, d) 7-chloroisatin, e) 4,7-dichloroisatin and 
f) 5,7-dichloroisatin as inhibitors. a) isatin. Substrate concentrations used (all µM) 
were: TDO, 300 (black), 350 (red), 500 (blue), 700 (orange), 800 (violet); IDO, 20 
(black), 25 (red), 35 (blue), 40 (orange), 45 (violet). b) 1-methylisatin. Substrate 
concentrations (µM) were: TDO, 300 (black), 350 (red), 400 (blue), 600 (orange), 
700 (violet); IDO, 20 (black), 25 (red), 35 (blue), 40 (orange), 45 (violet). c) 5-
chloroisatin. Substrate concentrations used (all µM) were: TDO, 300 (black), 350 
(red), 400 (blue), 500 (orange), 600 (violet); IDO, 25 (black), 30 (red), 35 (blue), 40 
(orange), 45 (violet). d) 7-chloroisatin. Substrate concentrations used (all µM) were: 
TDO, 300 (black), 350 (red), 500 (blue), 700 (orange), 800 (violet); IDO, 15 (black), 
20 (red), 25 (blue), 40 (orange), 45 (violet). e) 4,7-dichloroisatin. Substrate 
concentrations used (all µM) were: TDO, 300 (black), 400 (red), 500 (blue), 600 
(orange), 800 (violet); IDO, 15 (black), 25 (red), 35 (blue), 40 (orange), 45 (violet). 
f) 5,7-dichloroisatin. Substrate concentrations used (all µM) were: TDO, 250 (black), 
300 (red), 400 (blue), 600 (orange), 800 (violet); IDO, 15 (black), 25 (red), 30 (blue), 
40 (orange), 45 (violet).  




























































The effect of other halogens (F, Br and I) on isatin inhibition of TDO and IDO was 
also examined. Replacement of chlorine by fluorine, bromine or iodine atoms at 
either the 5- or 7-position of the indole ring revealed inhibition similar to the chloro-
substituted molecule (fig. 4.5).  Carefully examination of both 5- and 7- halogenated 
isatins revealed an increase of inhibition effectiveness based on the size of the 




Figure 4.5: Tryptophan catabolic activity of IDO (left column) and TDO (right 
column) in the absence and presence of 5’ halogenated (a, b) and 7’ halogenated 
isatins (c, d). Figures 1a, 1b (5’ halogenated isatins - 400 µM): Control- black (■), 
5-fluoroisatin -blue (∗), 5-chloroisatin - red (●), 5-Iodoisatin – purple (▲). Figures 
1c, 1d (7’ halogenated isatins - 400 µM): Control- black (■), 7-fluoroisatin – navy 
blue (∗), 7-chloroisatin - wine (●), 7-bromoisatin – olive (▼).  
 
 















































































































4.4 Breakdown of isatin 
 
After identifying isatin as a promising framework molecule for the potential 
development of TDO/IDO inhibitors, it was decided to attempt to characterise which 
part(s) of the molecule are most important in this respect. In particular, the aim was 
to examine the importance of the C2 and C3 carbonyl groups, the nitrogen atom and 





















The removal of the C3 carbonyl group of isatin produced 2-oxindole, a molecule 
with decreased inhibition activity compared to isatin itself (fig. 4.7). Comparing 2-
oxindole with 3,4-dihydro-2(1H)-quinolinone (the 6-membered ring analogue) it can 
be seen that the pyrrolidine ring of 2-oxindole is marginally more effective than the 
piperidine ring of 3,4-dihydro-2(1H)-quinolinone showing that the inhibition ability 
of these molecules is affected by the orientation of C2 carbonyl group and the ring 
size. The removal of the C2 carbonyl group was also investigated by examining the 
effect of indoline. From figure 4.7 it can be seen that indoline, of the four molecules 
studied, is the weakest inhibitor, especially in the case of TDO.  
 
 
Figure 4.7: Inhibition of hIDO (a) and hTDO (b) by isatin and isatin-related 
molecules. Control (no inhibitor) - black (■), indoline - red (∗), 3,4-dihydro-2(1H)-
quinolinone-olive(♦), 2-oxindole – blue (▲), isatin - orange(●). The final 
concentration of inhibitors was 400 µM. 
 
 
Given that the addition of chlorine to isatin was shown above to improve its 
inhibitory properties, the effect of chlorination of 2-oxindole and indoline was 
investigated. The ability of 5-chloro-2-oxindole and 5-chloroindoline to inhibit TDO 
and IDO is shown in figure 4.8, along with 5-chloroisatin. As may be expected, 5-
chloro-2-oxindole is a stronger inhibitor than 5-chloroindoline, something which 
comes in agreement with the findings for the non-chlorinated molecules. However, 
both molecules revealed a significantly decreased inhibition strength in comparison 
with 5-chloroisatin. 


























































Figure 4.8: Inhibition of hIDO (a) and hTDO (b) using 5-chloro-2-oxindole, 5-
chloroindoline and 5-chloroisatin as inhibitors. Control-black (■), 5-chloroindoline-
olive(●), 5-chloro-2-oxindole–blue(▲), 5-chloroisatin - red (∗).The final 




Having investigated the effect of altering the structure of isatin by removing the 
carbonyl groups, methylating the nitrogen atom, and changing the pyrrolidine ring to 
a piperidine ring, the next step was to investigate the effect of breaking the 5-
membered ring of isatin. In order to do this the following species were tested as 
inhibitors: N-(2,4-dichlorophenyl)acetamide, 2,5-dichloroformanilide, 2,4-dichloro-
N-methylaniline and 2,4-dichloroaniline, the structures of which are shown in figure 
4.9. As mentioned earlier, 5,7-dichloroisatin is a strong inhibitor of both TDO and 
IDO with inhibition constants of 800 nM and 6 µM respectively. Disrupting the 5-
membered ring of 5,7-dichloroisatin has the consequence of causing the molecule to 
lose its inhibition ability in both enzymes. None of the molecules shown in figure 4.9 














































































Figure 4.9: Chemical structures of N-(2,4-dichlorophenyl)acetamide, 2,5-
dichloroformanilide, 2,4-dichloro-N-methylaniline and 2,4-dichloroaniline. 
 
 
4.5 Substitution at the C3 position of isatin   
 
After showing the important role of the C3 carbonyl group for isatin’s inhibition 
activity, a number of C3-substituted derivatives of 5,7-dichloroisatin were tested as 
inhibitors of the two enzymes. These molecules were provided by the National 
Cancer Institute (USA). The structures of the molecules that were used are shown in 
figure 4.10 and their inhibition graphs in figure 4.11. All the inhibitors yielded 
inhibition constants in the low micromolar range for both TDO and IDO (Table 4.2). 
An overall observation of table 4.2 reveals that these compounds inhibit TDO more 
effectively than IDO. Among the seven NCI inhibitors shown in figure 4.10, NSC 
635312 and NSC 635297 demonstrated the lowest inhibition constants. Not 
surprisingly, replacement of a chlorine atom by a methyl group at 7’ position of the 
indole ring reduces the ability of NSC 635435 to inhibit TDO and IDO, something 
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that confirms the previous findings (see halogenation section). Removal of aniline 
group from NSC 635411 and replacement by naphthalene ring (NSC 635328) had no 
significant effect on TDO inhibition. Although, on IDO that change reduced the 
inhibition potency of the molecule. Comparing the structures of NSC 635297 with 
NSC 635306 it concluded that the two hydroxyl groups of NSC 635297 are likely to 
be involved in hydrogen bonding. Taking away the hydroxyl group of benzene ring 
and transforming the other one to ethylene oxide had a negative influence on both 
enzymes. In the case of NSC 625910, changes on the benzene group of the C3 site 
chain had not a spectacular effect on enzymes inhibition, inhibiting TDO and IDO at 
6.1 ± 0.5 µM and 10.7 ± 0.9 µM respectively. All inhibitors, presented in this 
section, have values from 1-12 µM for TDO, and 4-32 µM for IDO. Modifications at 
C3 do not appear to dramatically affect the inhibition strength of this family of 
molecules. However, modification at C3 seems to be important for inhibition activity 




Figure 4.10: Chemical structures of NCI inhibitors that were used in this study. 
NSC 635312  NSC 635435  NSC 635411  
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Figure 4.11: Dixon plots of hTDO (left column) and hIDO (right column) using a) 
NSC 635312, b) NSC 635435, c) NSC 635411, d) NSC 635328, e) NSC 635297, f) 
NSC 635306 and g) NSC 625910. a) NSC 635312. Substrate concentrations used (all 
µM) were: TDO, 300 (black), 350 (red), 400 (blue), 500 (orange), 600 (violet); IDO, 
15 (black), 20 (red), 25 (blue), 30 (orange), 35 (violet). b) NSC 635435. Substrate 
concentrations (µM) were: TDO, 300 (black), 350 (red), 400 (blue), 700 (orange), 
800 (violet); IDO, 15 (black), 25 (red), 30 (blue), 35 (orange), 45 (violet). c) NSC 
635411. Substrate concentrations used (all µM) were: TDO, 300 (black), 400 (red), 
500 (blue), 600 (orange), 700 (violet); IDO, 15 (black), 25 (red), 35 (blue), 40 
(orange), 45 (violet). d) NSC 635328. Substrate concentrations used (all µM) were: 
TDO, 300 (black), 400 (red), 500 (blue), 600 (orange), 800 (violet); IDO, 15 (black), 
20 (red), 25 (blue), 35 (orange), 40 (violet). e) NSC 635297. Substrate concentrations 
used (all µM) were: TDO, 300 (black), 400 (red), 500 (blue), 700 (orange), 800 
(violet); IDO, 17.5 (black), 20 (red), 25 (blue), 30 (orange), 32.5 (violet). f) NSC 
635306. Substrate concentrations used (all µM) were: TDO, 300 (black), 500 (red), 
600 (blue), 700 (orange), 800 (violet); IDO, 15 (black), 20 (red), 25 (blue), 35 
(orange), 45 (violet). g) NSC 625910. Substrate concentrations used (all µM) were: 
TDO, 400 (black), 500 (red), 600 (blue), 700 (orange), 800 (violet); IDO, 25 (black), 









































Table 4.2: Inhibition effectiveness of NCI inhibitors, shown in figure 4.10, against 
TDO and IDO 
 
 
4.6 Combination of 1-MT with isatin derivatives 
 
 In this section the behaviour of hIDO in the presence of 1-MT in combination with 
isatin derivatives is assessed. Given the specificity of IDO for 1-MT and the 
micromolar inhibition constants for the dichlorinated derivatives of isatin, the 
potential exists for these being a useful and potent inhibitor mixture for hIDO. The 
experiment was carried out as described in section 2.11. The findings of this trial are 
illustrated in figure 4.12. As expected, an increase in 1-MT concentration is related 
with a step-like increase of enzyme’s inhibition, which can reach 60% inhibition at 
400 µM 1-MT (fig. 4.12a-i). In the presence of 100 µM NSC 635312, IDO activity is 
inhibited by a percentage of ~80 %. Addition of 50 µM 1-MT has little appreciable 
effect on the overall inhibition observed, increasing further enzyme’s inhibition by a 










1.4 ± 0.4 µM 
 




5.5 ± 0.6 µM 
 




9.6 ± 0.8 µM 
 




8.4 ± 0.1 µM 
 




2.5 ± 0.6 µM 
 




12.5 ± 1.3 µM 
 




6.1 ± 0.5 µM 
 
10.7 ± 0.9 µM 
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the step-like reduction of IDO activity, pointing out the additive effect that 1-MT has 
in the presence of a stronger inhibitor (NSC 635312). Similar response was also 
observed in the cases of 5,7-dichloroisatin and 5-chloroisatin. In the presence of 100 
µM 5,7-dichloroisatin and 5-chloroisatin the enzyme activity reduced to ~18% and 
~38% respectively while addition of 1-MT revealed analogous to NSC 635312  step-
like reduction. In the case of NSC 635411, 100 µM of the NCI inhibitor and 50 µM 
of 1-MT have the same impact on IDO activity, reducing the uninhibited activity to 
~68 %. Combination of NSC 635411 with 1-MT (up to 100 µM) demonstrated little 
appreciable effect on the overall inhibition. Nevertheless, increase of 1-MT 
concentration from 100 µM to 200 µM improved noticeably the inhibition 
effectiveness of the mixture by 20 % extra inhibition. This effect remained constant 
up to 400 µM 1-MT. Mixing of NSC 635328 with 1-MT had a similar to NSC 
635411 response while the mixtures of NSC 635297, NSC 625910 and 7-chloroisatin 
with 1-MT revealed a unique behaviour. Addition of 50 µM 1-MT increased the 
effect of NSC 635297, NSC 625910 and 7-chloroisatin by 5%, 25% and 15%. 
However, this effect did not change in the presence of higher concentrations of 1-MT 
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Figure 4.12: Combination of 1-MT with the isatin derivatives; a) NSC 635312, b) 
NSC 635411, c) NSC 635328, d) NSC 635297, e) NSC 635306, f) NSC 625910, g) 
5,7-dichloroisatin, h) 5-chloroisatin and i) 7-chloroisatin. The black, blue, pink and 
navy blue columns represent 50 µM, 100 µM, 200 µM and 400 µM of 1-MT without 
and with 100 µM NCI inhibitors. In dark cyan is the NCI inhibitor/isatin derivative at 
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In this chapter a number of isatin derivatives have been investigated as potential 
inhibitors of IDO and TDO. Figure 4.13 illustrates the main outcomes. Starting with 
1-methylisatin it has been demonstrated that methylation of the nitrogen atom of 
isatin reduces the effectiveness of the produced inhibitor, something which suggests 
hydrogen bonding between the nitrogen atom and the active sites of both enzymes. 
Inhibition of TDO by 1-methylisatin also suggests that the molecule does not have 
the same orientation as 1-methyltryptophan, which is ineffective as a TDO inhibitor, 
presumably due to a clash with the active site histidine. This finding may explain 








The importance of halogenation of the 6-membered ring is also clear, showing an 
increase of the inhibition potency by 12-fold and 6-fold for TDO and IDO 
respectively. Increase of the inhibition potency of halogen-containing isatins might 
be related with the electronegativity of the halogen or it could be a steric effect. 
Whereas neither TDO nor IDO crystal structure with a halogenated isatin is currently 
available, both assumptions are equally possible.  
 The breakdown/removal of the pyrrolidine ring has a dramatic effect on the 
inhibition of both enzymes. 5,7-dichloroisatin inhibits TDO and IDO in the 
nanomolar and lower micromolar regions respectively, but without the presence of 
the pyrrolidine ring the molecule becomes an ineffective inhibitor, indicating that 
halogenation is favourable only when the indole moiety is intact. It has also been 
shown that the C2 carbonyl group is desirable for inhibition. The comparison 
between 2-oxindole and indole clearly shows that the carbonyl group at the C2 
position increases notably the inhibition effectiveness of the molecule. In addition, 
replacement of a pyrrolidine ring (5-membered) with a piperidine ring (6-membered) 
affects the relative orientation of the C2 carbonyl group, which in turn affects the 
efficiency of the inhibitor. Further to this, examination of the C3 carbonyl group 
showed that its removal has a negative result, similar to C2 carbonyl group removal. 
However, it can be replaced by two other functional groups, of which one should be 
a hydroxyl group, in order to retain its inhibitory properties. By comparing the 
outcomes of this work for both TDO and IDO, it can be said that these inhibitors are 
more effective for TDO than for IDO. In order to optimize IDO inhibition, 
combination of the IDO-specific 1-MT with the most potent dichlorinated inhibitors 
was tested. The results revealed an additive effect between the two kinds of 
inhibitors. In most of the cases, combination of 1-MT with the dichlorinated 
derivatives of isatin resulted in an increase in IDO inhibition by around 50% more 
than the inhibition effect offered by isatins alone.  This study aimed to identify, 
understand and develop a new class of IDO and TDO inhibitors. Through this 
examination, the potential for use of isatin and its derivatives as lead molecules has 
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Biochemical Characterization of Human Indoleamine 2,3-Dioxygenase-2 
 
5.1 Introduction  
 
Indoleamine 2,3-dioxygenase-2 (IDO2) is a third enzyme, along with tryptophan 2,3-
dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), that catalyses the 
incorporation of molecular oxygen into L-tryptophan in the first step of the 
kynurenine pathway (1). Human IDO2 (hIDO2) was discovered in 2007, and its 
encoding gene is adjacent to the human IDO (hIDO) gene on chromosome 8 (2), 
suggesting that it may have arisen as the product of gene duplication. Nevertheless, 
the distinct characteristics of hIDO2 raise the possibility of the protein having an 
immunomodulatory role unrelated to that of IDO. Studies in mice showed that both 
IDO and IDO2 are expressed in particular tissues (e.g. epididymis), supporting the 
idea of IDO2 implication in an unidentified signalling pathway (3).  
 In 2009, Löb et al. first suggested a possible role for IDO2 in cancer, 
demonstrating the presence of hIDO2 mRNA in gastric, colon and renal tumours (4). 
Following this, Sørensen et al. came to verify the importance of IDO2 in tumour 
escape and survival (5) by showing that in peripheral blood samples obtained from 
both healthy donors and cancer patients there was observed a spontaneous cytotoxic 
T-cell reactivity against IDO2. These T-cells were shown to be cytotoxic effector 
cells that recognize and kill tumour cells (5). The proposed involvement of IDO2 in 
cancer, in combination with the established immunomodulatory role of IDO, led to 
these enzymes being potential drug target molecules, and thus the identification and 
development of specific inhibitors for both enzymes is desirable. Studies on 1-
methylated tryptophan derivates have shown that 1-Me-D-Trp has superior in vivo 
antitumour activity compared with 1-Me-L-Trp (6). For this reason, 1-Me-D-Trp is 
currently the subject of clinical trials as an inhibitor of IDO enzymes 
(http://clinicaltrials.gov/show/NCT00739609). Considering the specificity of 1-Me-
L-Trp for IDO (4), 1-Me-D-Trp antitumour activity could be related to IDO2 
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function. However, the efficacy of 1-Me-D-Trp as an inhibitor of hIDO2 is yet to be 
evaluated. It has been variously reported that 1-Me-L-Trp is a more effective 
inhibitor of vertebrate IDO2 (7, 8) than 1-Me-D-Trp, and vice versa (9). In this chapter 
the characterisation of human IDO2 (hIDO2) with respect to substrate specificity (the 
various potential substrates that were tested are shown in Appendix B), 
electrochemical properties and inhibition selectivity is described. These data are 
compared with the corresponding data for IDO and potential similarities evaluated. 
This work in combination with previous findings suggests a physiological function 
for hIDO2 that is distinct from that of IDO. 
 
5.2 Determination of the optimum pH and buffer conditions 
 
Prior to the biochemical characterization of hIDO2 it was necessary to define the 
optimum pH for function of the enzyme. For this reason the activity of IDO2 was 
measured in 100 mM potassium phosphate buffer at pH values between pH 5.8 and 
8.0 (at intervals of 0.2 pH units). The findings clearly showed that optimal enzymatic 
activity occurs around pH 7.5 (figure 5.1). This finding is in good agreement with 
previously reported data for mouse IDO2 (mIDO2) where the optimal pH for activity 
was also found to be 7.5 (8). This is perhaps unsurprising, because the human and 
mouse enzymes have sequences that are 74% identical (13). Examination of several 
buffers at pH 7.5 indicated 100 mM potassium phosphate buffer as the most suitable 
for this study. 














Figure 5.1: Examination of hIDO2 optimum activity using 100 mM potassium 
phosphate buffer pH 5.8 - 8.0 
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5.3 Kinetic activity  
 
The kinetic parameters (kcat/Km, Km and kcat) obtained for hIDO2 activity with L-Trp, 
D-Trp and a number of tryptophan analogues are shown in table 5.1.The structures of 
the characterised substrates and their turnover plots are also shown in figures 5.2 and 
5.3 respectively. These molecules were chosen, from the 54 potential substrates that 
were screened, as the most effective substrates for IDO2. 
 
 
Name kcat / Km 
(M-1s-1)  








559 ± 23 
 







1664 ± 151 
 







2783 ± 174 
 







1708 ± 85 
 







679 ± 24 
 







6821 ± 63 
 






776 ± 42 
 








3798 ± 267 
 
0.0105 ± 0.0007 
 
Table 5.1: Kinetic characteristics for hIDO2 with L-Trp and other tryptophan 
analogues. The molecules were put in order starting with the best substrate for IDO2, 
based on kcat/Km values. Substrates such as 5-OH-L-Trp and melatonin revealed 






Figure 5.2: The structures of tryptophan derivatives that were used in this work 
 
From table 5.1 it can be seen that hIDO2 shows greatest catalytic efficiency with 5-
methoxy-D,L-tryptophan, largely due to its low Km value (559 ± 23 µM). 
Interestingly however, replacement of the 5-methoxy group by a methyl group has a 
negative influence in the binding of the molecule, decreasing its affinity 3-fold. On 
the other hand, this modification positively affects the turnover rate, increasing kcat 
from 0.143 ± 0.015 s-1 for 5-methoxy-D,L-tryptophan to 0.35 ± 0.01 s-1 for 5-methyl-
D,L-tryptophan. Furthermore, moving the methyl group from the 5- to the 6-position 
has the effect of decreasing both the affinity of the enzyme for the molecule and its 
turnover rate, resulting in a decrease in kcat/Km from 210 M
-1s-1 for 5-
methyltryptophan to 37 M-1s-1 for 6-methyltryptophan (Table 5.1). Regarding 5-
fluorotryptophan, it is shown that this molecule is a better substrate for IDO2 than 
the presumed natural substrate of the enzyme. 1-Me-L-Trp and L-Trp displayed 
similar overall efficiencies as substrates but clearly dissimilar kinetic parameters. 
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Binding of 1-Me-L-Trp is more favourable than binding of L-Trp, although L-Trp 
turnover occurs around 10 times faster than for 1-Me-L-Trp. In comparison with 1-
Me-L-Trp, the D-enantiomer of 1-Me-Trp showed a similar binding affinity (Km = 

































































































Figure 5.3: Michaelis-Menten plots for hIDO2 with a) 5-MeO-Trp, b) 5-Me-Trp, c) 






























































5.4 Inhibition activity 
 
 
Due to the discovery of IDO2 mRNAs in a variety of human cancers (4), and the 
strong inhibitory effect of 1-Me-D-Trp in mouse tumour models (6), it is desirable to 
clarify the selectivity of 1-methyltryptophan inhibition of IDO and IDO2. 
Consequently, the effectiveness of inhibition was investigated with D-Trp, 1-Me-L-
Trp and 1-Me-D-Trp as inhibitors of recombinant human IDO2, and the findings are 
illustrated in figure 5.4 
 
 





















Figure 5.4: Dixon plots of hIDO2 using a) 1-Me-L-Trp, b) 1-Me-D-Trp and c) D-
Trp. a) 1-Me-L-Trp. Substrate concentrations used (all mM) were: 1 (black), 2 (red), 
3 (blue), 4 (orange), 6 (violet). b) 1-Me-D-Trp. Substrate concentrations (mM) were: 
1 (black), 2 (red), 3 (blue), 4 (orange), 6 (violet).c) D-Trp. Substrate concentrations 
used (all mM) were: 1 (black), 2 (red), 3 (blue), 5 (orange), 7 (violet) 
 

































The fairly high affinities (low Km) of both 1-Me-L-Trp and 1-Me-D-Trp for the 
enzyme, (Km= 679 ± 24 µM and 776 ± 42 µM respectively) in combination with 
their poor turnover rates, enable inhibition of IDO2 by both molecules. In contrast 
with these methylated derivatives, D-Trp showed weak binding affinity and is 
unlikely to represent an effective inhibitor of the enzyme. These findings are 
summarised in table 5.2. For comparison, data for hIDO are also given. 
 
 
L-Trp D-Trp 1-Me-L-Trp 1-Me-D-Trp  
Ksi (µM) Ki (µM) Ki (µM) Ki (µM) 
hIDO 50 543 ± 35 18.0 ± 3.4 ni 
hIDO2 ni 12460 ± 562 306 ± 17 3419 ± 259 
 
Table 5.2: Inhibition data of hIDO and hIDO2 using D-Trp, 1-Me-L-Trp and 1-Me-
D-Trp as inhibitors. 
 
 
These results clearly show that, of these molecules, 1-Me-L-Trp is the best inhibitor 
of human IDO2. In comparison with the D-enantiomer, 1-Me-L-Trp is ~10-fold more 
potent as an inhibitor. Considering that 1-Me-D-Trp is not found to inhibit IDO, the 
weak inhibition ability of the molecule on IDO2 should be mentioned. In line with 
the turnover data, D-Trp is an implausible inhibitor of IDO2 with an inhibition 
constant of 12460 ± 562 µM. In comparison with IDO, it is clear that IDO2 
demonstrates differing behaviour against L-Trp and its analogues. Indeed, in the case 
of IDO, L-Trp substrate inhibition is observed. This phenomenon is not observed for 











5.5 Redox Potentiometry 
 
 
In addition to kinetic and inhibition studies, the electrochemical behaviour of IDO2 
was examined in the presence of L-Trp, D-Trp and their N-methylated analogues. 
Using the above substrates the reduction potentials of substrate-free and substrate-
saturated IDO2 were measured, and the results are shown in table 5.3. For 
comparison, data for hIDO are also given. 
 
Substrate Em  hIDO (mV vs. SHE) Em  hIDO2 (mV vs. SHE) 
 
Free - 54 ± 8 -49 ± 1 
L-Trp -16 ± 6 -9 ± 1 
D-Trp -57 ± 12 -6 ± 3 
1-Me-L-Trp -48 ± 8 -27 ± 3 
1-Me-D-Trp -55 ± 4 -46 ± 6 
 
Table 5.3: Reduction potentials of hIDO and hIDO2 as free enzyme or saturated 
with D-Trp, 1-Me-L-Trp and 1-Me-D-Trp. 
 
While the mid point potential of substrate free IDO2 is Em = -49 ± 1 mV, saturation 
of the enzyme with L-Trp caused a positive shift in the potential of 40 mV (fig. 5.5). 
Although this shift is smaller than that observed human TDO (chapter 3), it reflects 
the changes that occur in the heme environment during binding of L-Trp. This shift 
indicates stabilization of the reduced form in the presence of the ligand and may be 
roughly correlated with the ligand affinity. Interestingly, a similar shift in midpoint 
potential was observed in the presence of D-Trp. Further to this, the reduction 
potential obtained in the presence of 1-Me-L-Trp was positively shifted by 22 mV 
relative to the substrate-free enzyme, around half the magnitude of the shift that 
occurred with L-Trp and D-Trp. In contrast with 1-Me-L-Trp, binding of 1-Me-D-
Trp results in no change in the midpoint potential. The redox behaviour of hIDO2 
shows distinct dissimilarities with that of hIDO. In the absence of any ligand or in 
the presence of L-Trp both enzymes display similar midpoint potentials, but only for 
IDO2 does binding of D-Trp induce a similar shift in potential. In the case of 1-Me-
L-Trp and 1-Me-D-Trp, IDO2 again shows interesting behaviour. While in the 
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presence of 1-Me-D-Trp both IDO and IDO2 possess similar midpoint potentials, in 
the presence of 1-Me-L-Trp the two enzymes differ in their response. IDO is not 
significantly affected by 1-Me-L-Trp binding, retaining its midpoint potential at that 
of the free enzyme (Em = -48 mV), whilst IDO2 reveals a small but noticeable 
modulation in potential, from -49 mV to -27 mV. 
 
 








































5.6 Comparison of IDO with IDO2 
 
The study of IDO2 substrate and inhibition specificity in combination with its 
electrochemical characteristics shows that the enzyme is very inefficient as an L-Trp 
dioxygenase, the physiological function of IDO. Firstly, the two enzymes have 
different pH-activity profiles, with an optimum pH of 6.5 for IDO, and 7.5 for IDO2. 
Regarding the kinetic parameters (Km, kcat) and substrate specificity of the two 
enzymes, important dissimilarities were observed. Data for IDO and IDO2 are 
summarised and presented below (Table 5.4). 
 
 hIDO   hIDO2 
Substrate kcat (s
-1) Km (µM) kcat (s
-1) Km (µM) 
L-Trp 2. 97 ± 0. 20  20. 90 ± 3. 95 0.100 ± 0.005 6821 ± 63 
D-Trp 2. 7 ± 0. 3 296 ± 19 0.0105 ± 0.0007 3798 ± 267 
1- Me-L-Trp 0.062 ± 0.001 70 ± 1 0.011 ± 0.005 679 ± 24 
1-Me-D-Trp 0. 095 ± 0. 007 660 ± 43 0.0050 ± 0.0002 776 ± 42 
5-F-D,L-Trp 0.76 ± 0. 01 (14) 6.0 ± 0.8 0.048 ± 0.002 1708 ± 85 
5-Me-D,L-Trp 3.78 ± 0. 16 (14) 98 ± 14 0.35 ± 0.01 1664 ± 151 
5-HO-L-Trp 0.0250 ± 0.0004 (14) 17.0 ± 1.1 No activity - 
 
Table 5.4: Kinetic characteristics for hIDO and hIDO2 using L-Trp and other 
tryptophan analogues as substrates. Data for hIDO with 5-F-D,L-Trp, 5-Me-D,L-Trp 
and 5-HO-L-Trp were taken from ref. 14. Assays of IDO and IDO2 were carried out 
in 100 mM KPi pH 6.5 and 7.5 respectively. 
 
 
Molecules such as 5-MeO-D,L-Trp and 6-Me-D,L-Trp are shown to be substrates for 
IDO2, something which has not been reported so far for IDO. In this chapter the 
potency of 5-HO-L-Trp and melatonin as substrates for IDO2 is also determined. 
While neither showed any activity for IDO2, 5-HO-L-Trp is a published substrate of 
IDO with good affinity for the enzyme (Km = 17.0 ± 1.1 µM) but poor turnover rate 
(kcat = 0.0250 ± 0.0004 s
-1) (14). Interestingly, 5-Me-D,L-Trp was found to be, 
relatively speaking, a very good substrate for IDO2 and a very poor substrate for 
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IDO. Like 5-Me-D,L-Trp, 5-F-D,L-Trp demonstrated two different behaviours for 
IDO and IDO2. In the case of IDO, 5-F-D,L-Trp is an important substrate with 
activity similar to that found for L-Trp (Table 5.4). In addition, 5-F-D,L-Trp showed 
high affinity for the enzyme (Km = 6 ± 0.8 µM), higher even than the L-Trp Km value 
(20. 9 ± 3. 95 µM). For IDO2 though the findings differ, with the 5-fluoro substrate 
showing lower activity than 5-Me-D,L-Trp. Examination of L-Trp turnover revealed 
surprising kinetic parameters for IDO2. According to the various enzymatic 
efficiencies presented in figure 5.6, L-Trp is the fourth most active substrate for 
IDO2 after 5-Me-D,L-Trp,  5-F-D,L-Trp and 1-Me-L-Trp, with a level of activity 
which seems unlikely to be biologically relevant. Amongst the several molecules that 
have been characterised as substrates for IDO2, the L-Trp data revealed the worst 
binding affinity (Km = 6821 ± 63 µM).  
 
Figure 5.6: a) IDO and b) IDO2 catalytic response against L-Trp and other 
tryptophan analogues.  
 
 
Both 1-Me-L-Trp and 1-Me-D-Trp seem to fulfil the characteristics of a good 
inhibitor for IDO2 (high affinity and low turnover rates) in contrast with IDO where 
1-Me-L-Trp excels. Considering all the data, it appears that 1-Me-L-Trp is the best 
























































































































The aim of this study was to examine the biochemical behaviour of recombinant 
human IDO2 and from there to extract useful conclusions about its function and 
catalytic preferences. In addition to this, the specificity of inhibition of IDO and 
IDO2 by the two isomers of 1-MT was investigated, in the light of recent 
publications on the antitumour activity of 1-Me-D-Trp. From all of this work it can 
be seen that hIDO differs significantly from hIDO2. The pH profile, substrate and 
inhibition specificity and the redox behaviour show distinct differences between the 
two enzymes. Although these findings cannot exclude the chance of IDO2 being an 
evolutionary ancestor of IDO, expression of both enzymes in particular tissues (3) in 
combination with the verified importance of IDO2 in tumour escape and survival (5) 
suggest that the enzyme is likely to be involved in an identified biological pathway. 
With respect to the two isomers of 1-MT, in vitro studies of the enzyme identified 1-
Me-L-Trp as the more likely inhibitor for IDO2, leaving question marks over the 
origins of the antitumour activity of 1-Me-D-Trp. While the inhibition constant for 
IDO2 with 1-Me-D-Trp (Ki = 3419 ± 259 µM) suggests that the molecule cannot 
inhibit the enzyme effectively, the enzyme’s affinity for the same molecule (Km= 776 
± 42 µM) comes in conflict with the above result. Although this chapter provides 
important information about the behaviour of hIDO2 in vitro, its biological 
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6.1 Previously published inhibitors 
 
The study of various known inhibitors of TDO and IDO has led to clarification of 
their specificity against either enzyme. The only specific inhibitor of IDO, 1-MT, 
will be discussed in the following section, while pyridyls revealed no specificity for 
TDO. The inhibition potency of these molecules is a subject of argument between 
this work and the previously published results (1). According to Madge and co-
workers, in vitro examination of 2-, 3- and 4-pyridyl compounds (40-60% purity) 
provided inhibition constants between 30-100 nM. The screening results presented 
here, though, show fairly weak inhibition with inhibition constants in the region of 
>100 µM. Considering the low purity of their samples, this disagreement is possibly 
related to the high percentage of contamination which could easily affect assay 
accuracy. Synthesis and purification of the pyridyl inhibitors used here was 
undertaken by Dr. Sarah J. Thackray and after NMR examination, they were 
characterized as ≥90% pure. 
 Examination of ebselen, a published inhibitor of IDO, yielded information 
which may be useful for the future optimization of TDO purification and 
crystallisation. Because of the unsatisfactory level of heme occupancy in 
preparations of human TDO, trials to crystallise the protein led to either formation of 
microcrystals or amorphous non-diffracting material. A standard procedure that is 
often followed for optimization of the purification process is substitution of a 
protein’s cysteine residues in order to prevent dimerisation/oligomerisation via 
disulfide bond formation. Studies with ebselen showed that in the case of TDO, 
cysteine substitution could optimise the purification process. The construction of a 
model of hTDO, based on the structure of X. campestris TDO (by Dr. Sarah J. 
Thackray) showed that Cys4 is likely to be located on the surface of the protein and 
therefore its substitution will be a priority. 
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6.2 The specificity of 1-methyltryptophan for IDO and IDO2 
 
With regard to 1-MT, it can be said that the molecule shows a clear selectivity for 
IDOs. The L-isoform of 1-MT is the only valid inhibitor for IDO while IDO2 
findings do not provide a clear answer. Despite the fact that both 1-Me-L-Trp and 1-
Me-D-Trp revealed similar Km values for IDO2 (679 ± 24 µM and 776 ± 42 µM for 
1-Me-L-Trp and 1-Me-D-Trp respectively) the inhibition outcomes (1-Me-L-Trp Ki= 
306 ± 17 µM and 1-Me-D-Trp Ki= 3419 ± 259 µM) show a clear preference of the 
enzyme for the L-isomer over the D-isomer. Important to report is that the data 
presented herein explains only the in vitro behaviour of recombinant IDO and IDO2. 
The higher anticancer potency of 1-Me-D-Trp, in vivo, is still to be explained.  
 
6.3 National Cancer Institute (NCI) inhibitors 
 
Having examined a significant number of TDO and IDO potential inhibitors (~ 
3000), a series of inhibitors for both enzymes was subsequently identified and 
characterised. For the NCI compounds, seven molecules with robust inhibition 
activity against both enzymes were discovered (Table 3.6). In addition to their 
inhibition action against TDO and IDO, these molecules were also found be active in 
tumour cell assays (as mentioned in Chapter 3). All seven revealed synergism with 1-
MT for inhibition of IDO. Because of their sizes and structural variety, the inhibitors 
NSC 26326, NSC 36398, NSC 111041 and NSC 261726 will be studied further 
(structures fig. 3.13). The previous encouraging published result for NSC 26326 (2)-(5) 
(low toxicity to normal tissue, selectivity against cancer cells and a synergistic effect 
with radiation therapy) in combination with the strong inhibition activity that the 
molecule has on TDO and IDO give confidence that the further study of β-lapachone 
can produce a new class of promising inhibitors. Additionally, it is important to note 
the good inhibition potency of the flavone-like inhibitor, NSC 36398, on TDO in 
contrast with IDO. Having as an ultimate goal the development of a specific inhibitor 
for TDO, the study of this family will continue. Whilst NSC 111041 and NSC 
261726 are not well studied inhibitors, further examination of these molecules is 
necessary.  
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6.4 Isatin derivatives 
 
The effort that has been made towards the development of a new class of TDO and 
IDO inhibitors has resulted in the identification of a new class of inhibitors with 
inhibition constants in the low micromolar range. Starting with isatin itself, and after 
making various structural various modifications, a number of promising inhibitors 




Figure 6.1: Illustration of the trials that have been made towards the identification 
and characterization of the potent inhibitors with general structure 6. These 
molecules revealed the highest inhibition activities for both TDO and IDO and 








X   = halogen 
R   = aliphatic group  
R1 = -OH 
R2 = aliphatic/aromatic group  
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Trials involving modification of the core moiety of isatin had the result of decreasing 
the inhibition potency of these molecules (fig. 6.2). None of the molecules shown in 
figure 6.2 showed inhibition of either TDO or IDO. However, while molecules with 
the general structure 6 in figure 6.1 provided satisfactory inhibition activities, trials 
to optimize their inhibition properties will continue. A series of modifications at the 
C3 atom of the indole ring will help gain further understanding of the effect that the 
C3-modifications have on inhibition of TDO and IDO. 
 
Figure 6.2: Modifications of isatin that result in the loss or decrease of its inhibition 
potency. 
 
6.5 Characterization of IDO2 
 
In vitro examination of hIDO2 was undertaken in order to clarify the enzyme’s 
biological role. Clearly IDO2 demonstrated noticeable dissimilarities in comparison 
with IDO. Because of its weak in vitro ability to produce L-kynurenine, it can be said 
that IDO2 is unlikely to have an active role in the kynurenine pathway. Assuming 
that the enzyme is biologically redundant, its efficiency with 5-MeO-Trp and 5-Me-
Trp raises questions. Although this study offered important information regarding 
IDO2 in vitro behaviour, in vivo study of the enzyme is needed to securely determine 
to what degree IDO1 and IDO2 are similar in their preference for substrates and 
reaction pathways to generate product.  
Isatin 
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6.6 Future work 
 
The inhibition outcomes of the current thesis provide a number of inhibitors with 
good inhibition potencies (in either nanomolar or low micromolar range) for both 
hTDO and hIDO. Utilizing the previous published crystal structures of xcTDO (6) and 
hIDO (7), it will pursue their co-crystallization with particular inhibitors such as NSC 
26326 (97 ± 14 nM IDO and 30-70 nM TDO), NSC 36398 (>100 µM IDO and 16.3 
± 3.8 µM TDO) and NSC 111041 (4.3 ± 0.9 µM IDO and 1.1 ± 0.3 µM TDO) (for 
structures see fig 3.13). Preliminary crystallographic results of xcTDO with NSC 
26326 indicate that binding of inhibitor(s) into the active site pocket of the enzyme is 
likely to occur only in the ferrous active form. In addition, mutagenesis of active site 
residue(s) that are involved in the induced fit motion of xcTDO might help as well. 
In our trial to obtain the crystal structure of hTDO, mutation of Cys4 residue will be 
attempted in line with co-crystallisation of the mutant with NSC 26326. 
 The most promising inhibitors, identified herein, will be used as templates for 
the development of new inhibitors of hTDO and hIDO. NSC 36398 is the only 
inhibitor that revealed selectivity for hTDO and thus study of this molecule will 
continue. Following the development of the daughter inhibitors, their inhibition 
activity will be evaluated both in vitro and in vivo. Combinations of 1-MT (hIDO 
only) with the newly developed inhibitors will be examined and their toxicity in a 
cell based assay will be assessed. Regarding the isatin derivatives, a number of new 
modifications (replacement of C2 carbonyl oxygen with fluorine and substitutions of 
C5 and C3 atoms) will be tried and their activity in a cell based assay will be 
evaluated as well. 
 Examination of 1-Me-L-Trp and 1-Me-D-Trp inhibition activity against 
hIDO and hIDO2 provides information in regards with the in vitro behaviour of these 
inhibitors. Although these results come in agreement with the cell-based findings of 
1-Me-L-Trp, they can not explain the high anticancer potency of 1-Me-D-Trp (8). 
Using affinity proteomics it will be attempted to identify new in vivo targets of 1-
Me-D-Trp (9). Identification of new in vivo targets of 1-Me-D-Trp will provide 
insight into the molecule’s anticancer potency and will help us to understand better 
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the way that 1-MT functions. Last but not least is hIDO2. All the results presented in 
this work support the idea that hIDO2 function in vivo is still to be clarified. The 
enzyme shows a clear role in cancer biology and obvious differences from hIDO. 
High-throughput screening (HTS), for the identification of small molecules that act 
either as substrates or inhibitors, can provide useful information regarding the actual 
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Number Name MW (g/mol) Supplier 
0 L-tryptophan 204.3 Sigma/Aldrich 
1 D-tryptophan 204.23 Sigma/Aldrich 
2 indole 117.15 Sigma/Aldrich 
3 5-methyl-D/L-tryptophan 218.26 Sigma/Aldrich 
4 3-(2-hydroxyethyl) indole 161.21 Sigma/Aldrich 
5 Nα-me-L-tryptophan 216.26 Sigma/Aldrich 
6 5-hydroxyindole 133.15 Sigma/Aldrich 
7 6-methyl-D/L-tryptophan 218.25 Sigma/Aldrich 
8 L-kynurenine 208.2 Sigma/Aldrich 
9 3-hydroxykynurenine 224.2 Sigma/Aldrich 
10 benzofuran-2-yl-me-ketone 160.17 Sigma/Aldrich 
11 indole-3-carboxaldehyde 145.15 Sigma/Aldrich 
12 L-tryptophanol 190.25 Sigma/Aldrich 
13 indole-3-acetic acid 175 Sigma/Aldrich 
14 1-methyl-D-tryptophan 218.26 Sigma/Aldrich 
15 Boc-D-3-benzothiethylalanine 321.4 Sigma/Aldrich 
16 3-D/L-indoleacetic acid 175 Sigma/Aldrich 
17 melatonin 232.28 Sigma/Aldrich 
18 indole 3-acetamide 174.2 Sigma/Aldrich 
19 5-fluoro-D/L-Tryptophan 222.22 Sigma/Aldrich 
20 L-alanine 89.09 Sigma/Aldrich 
21 benzofuran-3-acetonitrile 157.17 Sigma/Aldrich 
22 3-indoleacrylic acid 187.2 Sigma/Aldrich 
23 4-(1H-imidazol-1-yl) aniline 161.21 Sigma/Aldrich 
24 4-(imidazol-1-yl) phenol 162.19 Sigma/Aldrich 
25 L-histidine 155.2 Sigma/Aldrich 
26 L-homoserine 105.09 Sigma/Aldrich 
27 Fmoc-β-(3-benzothienyl)-L-alanine 443.52 Sigma/Aldrich 
28 2-pyridyl 219 In house 
29 R963453 305.338 Sigma/Aldrich 
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30 S065081 224.223 Sigma/Aldrich 
31 3-(2-(2-pyridyl)ethyl) indole  222.291 Sigma/Aldrich 
32 s293520 211.228 Sigma/Aldrich 
33 3-pyridyl 219 In house 





36 1H -1,2,3-triazol 69.07 Sigma/Aldrich 
37 2,2-dithiodipyridyl 220 Sigma/Aldrich 
38 C10H11O3N 193.2 St Andrews 
39 C10H17O3N 199.25 St Andrews 
40 C14H13O3N 243.26 St Andrews 
41 C9H12O4NP 229.17 St Andrews 
42 C12H13O3N 219.24 St Andrews 
43 C11H11O3N 205.21 St Andrews 
44 C10H10O5N 260.65 St Andrews 
45 C10H10O3NCl3 298.55 St Andrews 
46 A2425/0102738 227.257 Ambinter 
47 A0345/0015908 263.275 Ambinter 
48 PHAR061831 - 28SPH1-397-776 256.261 Ambinter 
49 STOCK1S-37397 354.388 InterBioScreen 
50 STOCK5S-29375 234.295 InterBioScreen 
51 STOCK1S-38338 260.359 InterBioScreen 
52 STOCK2S-19248 305 InterBioScreen 
53 T3018147 279.255 Tim Tec 
54 T3175372 274.28 TimTec 
55 ST5026463 271.316 Tim Tec 
56 ST009518 221.263 TimTec 
57 1-methyl-L-tryptophan 218 Sigma/Aldrich 
58 7-chloro-L-tryptophan 238 St Andrews 
59 norharman 168.19 Sigma/Aldrich 
60 JFD00036 209 Maybridge  
61 r433950 207.237 Sigma/Aldrich 
62 r493171 235.291 Sigma/Aldrich 
63 r351687 406.229 Sigma/Aldrich 
64 s293520 211.228 Sigma/Aldrich 
65 11B-126 190.22 Key organics 
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66 10w-0241 301.08 Key organics 
67 t0516-4089 319.3 Enamine 
68 T3227834 270.288 Tim Tec 
69 ST042376 266.222 Tim Tec 
70 T3012398 240.328 Tim Tec 
71 ST245307 257.289 Tim Tec 
72 anthraquinone 2-sulfonate 288 Sigma/Aldrich 
73 2-hydroxy-1,4-napthaquinone 174 Sigma/Aldrich 
74 5- hydroxy-1,4-nathaquinone 174 Sigma/Aldrich 
75 1,2-napthaquinone 158 Sigma/Aldrich 
76 5,8-dihydroxy-1,4-napthaquinone 190 Sigma/Aldrich 
77 anthroquinone- 2,6- disulfonic 412 Sigma/Aldrich 
78 1,4-napthoquinone 158 Sigma/Aldrich 
79 2-methyl-1,4-benzoquinone 122 Sigma/Aldrich 





82 tetrachloro-ortho-benzoquinone 238 Sigma/Aldrich 
83 1,2-napthaquinone-4-sulfonic acid 172 Sigma/Aldrich 
84 anthraquinone 184 Sigma/Aldrich 









88 indigo 262.26 Sigma/Aldrich 
89 isatin 147.13 Sigma/Aldrich 
90 benzophenone 182.21 Sigma/Aldrich 
91 2-indanone 132.16 Sigma/Aldrich 
92 6-methyl-indan-1-one 146.18 Sigma/Aldrich 
93 unknown 226 Sigma/Aldrich 
94 NSC1460 205.22 NCI 
95 NSC14159 160.19 NCI 
96 NSC22128 221.263 NCI 
97 NSC106090 212.27 NCI 
98 NSC175825 385.241 NCI 
99 NSC103253 338 NCI 
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100 mitomycin C 334.33 Tocris Biosc. 
101 carbazole 167.206 Sigma/Aldrich 
102 riboflavin  376.36 Sigma/Aldrich 
103 SPB08034 235.305 RyanScientific 
104 KM04716 286.379 RyanScientific 
105 KMO08843 246.226 RyanScientific 
106 S760269 235.242 Sigma/Aldrich 
107 S42065 205.215 Sigma/Aldrich 
108 CA 199 306 Leicester Uni.  














b-nicotinamide adenine dinucleotide 
phosphate (b-NADP) 
765.4 Sigma/Aldrich 
114 flavin adenine dinucleotide (FAD) 829.5 Sigma/Aldrich 
115 







117 adenosine 267.2 Sigma/Aldrich 
118 
adenosine 5'-triphosphate disodium 
salt 
551.1 Sigma/Aldrich 
119 guanine 151.13 Sigma/Aldrich 
120 unknown 222 Sigma/Aldrich 
121 biotin 244.31 Sigma/Aldrich 
122 thiamine 337.27 Sigma/Aldrich 
123 pyridoxine hydrochloride 205.64 Biochemical 
124 lumiflavin 256.3 Sigma/Aldrich 
125 5,7-dichloroisatin 216.02 Sigma/Aldrich 
126 chlophacinon 374.82 Sigma/Aldrich 
127 1-cyclohexyluracil 194.2 Sigma/Aldrich 
128 allethin 302.41 Sigma/Aldrich 















134 uracil 112.1 Sigma/Aldrich 
135 thymine 126.11 Sigma/Aldrich 




















141 2-benzoyl-cyclopentanone 188.288 Sigma/Aldrich 
142 1,3-indandion 146.15 Sigma/Aldrich 
143 2-acetyl-1,3-indanedione 188.18 Sigma/Aldrich 
144 citalopram 324 Sigma/Aldrich 
145 6,8-dichloro-3-methylchromone 229.06 Sigma/Aldrich 
146 5,7-dichloro-1-indanone 201.05 Sigma/Aldrich 
147 5,7-dichloro-8-quinolinol 214.05 Sigma/Aldrich 
148 5-chloroisatin 181.58 Sigma/Aldrich 





151 quercetin hydrate 302.24 Sigma/Aldrich 
152 myricetin 318.24 Sigma/Aldrich 














157 flavone 222.24 Sigma/Aldrich 
158 ebselen 274.2 Cayman 
159 NSC 635312 412 NCI 
160 NSC 635326 381 NCI 
161 NSC 635435 392 NCI 
162 NSC 167410 448 NCI 
163 NSC 100445 306 NCI 
164 NSC 123115 376.4 NCI 


































175 1,4-dihydroxy-2-naphthoic acid 204.19 Sigma/Aldrich 
176 5-chloroindole 151.59 Sigma/Aldrich 
177 5-chloro-2-oxindole 167.59 Sigma/Aldrich 
178 2-oxindole 133.15 Sigma/Aldrich 
179 indoline 119.17 Sigma/Aldrich 
180 3,4-dihydro-2(1H)-quinolinone 147.18 Sigma/Aldrich 
181 2-hydroxybenzimidazole 134.14 Sigma/Aldrich 
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182 N-(2,4-dichloroohenyl)acetamide 204.057 Sigma/Aldrich 
183 6-chlorobenzoxazol-2(3H)-one 169.57 Sigma/Aldrich 
184 4,5-dichlorophthalimide 216.02 Sigma/Aldrich 
185 N-acetylphthalimide 189.17 Sigma/Aldrich 
186 CH47471 153.61 TimTec 
187 2,4-dichloroaniline 162.02 Sigma/Aldrich 
188 2,4-dichloro-N-methylaniline 176.04 Sigma/Aldrich 
189 3-hydroxyanthranilic acid 153.14 Sigma/Aldrich 





192 2,5-dichloroformanilide 190.03 Sigma/Aldrich 





195 6,8-dinitro-1,2-dihydro-quinolin-2-ol 237.173 Sigma/Aldrich 
196 salicylic acid 138.12 Sigma/Aldrich 
197 2-amino-3-chlorobenzoic acid 171.58 Sigma/Aldrich 
198 2-amino-3-methylbenzoic acid 151.16 Sigma/Aldrich 
199 anthranilic acid 137.14 Fluka 
200 ST4146353 220.23 TimTec 
201 pn20 230.05 St. Andrews 
202 pn14 288.13 St. Andrews 
203 pn21 303.14 St. Andrews 
204 7-bromoisatin 226.03 Sigma/Aldrich 
205 7-fluoroisatin 165.12 Sigma/Aldrich 
206 5-iodoisatin 273.03 Sigma/Aldrich 












Number Name MW Supplier 
1 L-tryptophan 204.3 Sigma/Aldrich 
2 D-tryptophan 204.3 Sigma/Aldrich 
3 indole 117.15 Sigma/Aldrich 
4 5-methyltryptophan 218.26 Sigma/Aldrich 
5 3-(2-hydroxyethyl) indole 161.21 Sigma/Aldrich 
6 5-hydroxyindole 133.15 Sigma/Aldrich 
7 6-methyltryptophan 218.25 Sigma/Aldrich 
8 L-kynurenine 208.2 Sigma/Aldrich 





11 indole-3-carboxaldehyde 145.15 Sigma/Aldrich 
12 L-tryptophanol 190.25 Sigma/Aldrich 
13 indole-3-acetic acid 175 Sigma/Aldrich 
14 1-methyl-D-tryptophan 218.26 Sigma/Aldrich 
15 1-methyl-L-tryptophan 218.26 Sigma/Aldrich 
16 melatonin 232.28 Sigma/Aldrich 
17 indole 3-acetamide 174.2 Sigma/Aldrich 
18 5-fluorotryptophan 222.22 Sigma/Aldrich 
19 L-alanine 89.09 Sigma/Aldrich 
20 benzofuran-3-acetonitrile 157.17 Sigma/Aldrich 





23 L-histidine 155.2 Sigma/Aldrich 
24 2-pyridyl 219 in house 
25 C10H11O3N 193.2 st andrews 
26 C14H13O3N 243.26 st andrews 
27 7-chlorotryptophan 238 St Andrews  
 157 
28 norharman 168.19 Sigma/Aldrich 
29 10w-0241 301.08 key organics 
30 isatin 147.13 Sigma/Aldrich 
31 2-indanone 132.16 Sigma/Aldrich 
32 6-methyl-indan-1-one 146.18 Sigma/Aldrich 
33 NSC1460 205.22 NCI 
34 NSC106090 212.27 NCI 
35 carbazole 167.206 Sigma/Aldrich 





38 5,7-dichloro-1-indanone 201.05 Sigma/Aldrich 
39 5-chloroindole 151.59 Sigma/Aldrich 
40 2-oxindole 133.15 Sigma/Aldrich 














46 3-hydroxyanthranilic acid 153.14 Sigma/Aldrich 
47 kynurenic acid 189.17 Sigma/Aldrich 





50 ST4146353 220.23 Tim Tec 
51 indene 116.16 Sigma/Aldrich 
52 s-tryptophan 207.2 in house 
53 indole-3-glyoxylic acid 189.167 Sigma/Aldrich 









The amino acid sequences of TDO and IDO enzymes 
 
 
Xanthomonas Campestris TDO (Length: 298aa, Mass: 34,617 Da - His tag) 
 
 
        10         20         30         40         50         60  
MPVDKNLRDL EPGIHTDLEG RLTYGGYLRL DQLLSAQQPL SEPAHHDEML FIIQHQTSEL  
 
        70         80         90        100        110        120  
WLKLLAHELR AAIVHLQRDE VWQCRKVLAR SKQVLRQLTE QWSVLETLTP SEYMGFRDVL  
 
       130        140        150        160        170        180  
GPSSGFQSLQ YRYIEFLLGN KNPQMLQVFA YDPAGQARLR EVLEAPSLYE EFLRYLARFG  
 
       190        200        210        220        230        240  
HAIPQQYQAR DWTAAHVADD TLRPVFERIY ENTDRYWREY SLCEDLVDVE TQFQLWRFRH  
 
       250        260        270        280        290       







Human TDO (Length: 406aa, Mass: 47,872 Da - His tag) 
 
 
        10         20         30         40         50         60  
MSGCPFLGNN FGYTFKKLPV EGSEEDKSQT GVNRASKGGL IYGNYLHLEK VLNAQELQSE  
 
        70         80         90        100        110        120  
TKGNKIHDEH LFIITHQAYE LWFKQILWEL DSVREIFQNG HVRDERNMLK VVSRMHRVSV  
 
       130        140        150        160        170        180  
ILKLLVQQFS ILETMTALDF NDFREYLSPA SGFQSLQFRL LENKIGVLQN MRVPYNRRHY  
 
       190        200        210        220        230        240  
RDNFKGEENE LLLKSEQEKT LLELVEAWLE RTPGLEPHGF NFWGKLEKNI TRGLEEEFIR  
 
       250        260        270        280        290        300  
IQAKEESEEK EEQVAEFQKQ KEVLLSLFDE KRHEHLLSKG ERRLSYRALQ GALMIYFYRE  
 
       310        320        330        340        350        360  
EPRFQVPFQL LTSLMDIDSL MTKWRYNHVC MVHRMLGSKA GTGGSSGYHY LRSTVSDRYK  
 
       370        380        390        400      




Human IDO (Length: 403aa, Mass: 45,326 Da - His tag) 
 
  
                         10         20         30         40                    
MRGSHHHHHHGSACELGTAHAMENSWT ISKEYHIDEE VGFALPNPQE NLPDFYNDWM  
 
        50         60         70         80         90        100 
FIAKHLPDLI ESGQLRERVE KLNMLSIDHL TDHKSQRLAR LVLGCITMAY VWGKGHGDVR 
 
       110        120        130        140        150        160    
KVLPRNIAVP YCQLSKKLEL PPILVYADCV LANWKKKDPN KPLTYENMDV LFSFRDGDCS 
 
       170        180        190        200        210        220 
KGFFLVSLLV EIAAASAIKV IPTVFKAMQM QERDTLLKAL LEIASCLEKA LQVFHQIHDH 
 
       230        240        250        260        270        280       
VNPKAFFSVL RIYLSGWKGN PQLSDGLVYE GFWEDPKEFA GGSAGQSSVF QCFDVLLGIQ 
 
       290        300        310        320        330        340 
QTAGGGHAAQ FLQDMRRYMP PAHRNFLCSL ESNPSVREFV LSKGDAGLRE AYDACVKALV   
 
       350        360        370        380        390        400 
SLRSYHLQIV TKYILIPASQ QPKENKTSED PSKLEAKGTG GTDLMNFLKT VRSTTEKSLL 
 





                           
Human IDO2 (Length: 407aa, Mass: 45,424 Da - His tag) 
 
 
                                    10         20         30                  
MSYYHHHHHHLESTSLYKKAGSAAAPFTMEPHRPNVKT AVPLSLESYH ISEEYGFLLP  
 
        40   50         60         70         80         90 
DSLKELPDHY RPWMEIANKL PQLIDAHQLQ AHVDKMPLLS CQFLKGHREQ RLAHLVLSFL 
 
       100        110        120        130        140        150 
TMGYVWQEGE AQPAEVLPRN LALPFVEVSR NLGLPPILVH SDLVLTNWTK KDPDGFLEIG 
 
       160        170        180        190        200        210 
NLETIISFPG GESLHGFILV TALVEKEAVP GIKALVQATN AILQPNQEAL LQALQRLRLS 
 
       220        230        240        250        260        270 
IQDITKTLGQ MHDYVDPDIF YAGIRIFLSG WKDNPAMPAG LMYEGVSQEP LKYSGGSAAQ 
 
       280        290        300        310        320        330 
STVLHAFDEF LGIRHSKESG DFLYRMRDYM PPSHKAFIED IHSAPSLRDY ILSSGQDHLL 
 
       340        350        360        370        380        390 
TAYNQCVQAL AELRSYHITM VTKYLITAAA KAKHGKPNHL PGPPQALKDR GTGGTAVMSF 
 
       400 









(i) Michaelis-Menten equation  
 
 
The Michaelis-Menten equation explains the kinetic behaviour of enzymes using the 
model shown in figure D1. According to that, the substrate (S) binds to the enzyme 
(E), reversibly, producing an intermediate enzyme-substrate (ES) complex which in 
turn produces the product (P). The reaction rates for formation of ES complex, E+ S 
and E+ P are given by k1, k2 and kcat respectively. In order to be valid, the Michaelis-
Menten model enquires two main assumptions. Firstly, the whole system must be in 
steady-state meaning that the complex ES remains constant regardless of ongoing 
processes to modify it and secondly the concentration of the enzyme is negligible 





Figure D1: Illustration of Michaelis-Menten model. The enzyme (E), substrate (S) 
and product (P) are shown in blue, red and orange colours respectively while the rate 
















Considering that we are talking for an isolated system, the total enzyme 
concentration [Etot] is equal to the concentration of free enzyme [E] plus the 
concentration of the substrate bound enzyme [ES]: 
 
 
[Etot] = [E] + [ES]  
                                                                                                                                                                                                                       
  
                                                                                                                          
 




























Because the system is in steady state the equation (3) is equal to zero. Rearrangement 

















































Graphical demonstration of Michaelis-Menten equation is shown in figure D2. 
 
































When the concentration of substrate is much higher that the Michaelis constant 









On the other hand, when the concentration of substrate is negligible compared to 








(ii) Lineweaver-Burk equation  
 
 
The Lineweaver-Burk equation is the reciprocal illustration of Michaelis-Menten 
equation (both sides), providing a linear analysis of enzymes kinetics. Combination 








The double reciprocal rearrangement of equation (10) provides the Lineweaver-Burk 




































Macromolecular inhibition studies indicated two major classes of enzyme inhibitors, 
the non-specific inhibitors and the specific ones. While the non-specific inhibitors 
affect all the enzymes in the same way, the specific inhibitors act on particular 
enzymes attracting in that way all the interest of the drug development industry. This 
class of inhibitors can be further classified into irreversible and reversible. This 
section is dedicated to reversible inhibitors so whatever presents below refers to 
them. According to the position of binding, the reversible inhibitors can be grouped 
into competitive, uncompetitive and non-competitive. The models of their action are 








i) Competitive type of inhibition 
 
 
The competitive inhibitors act by “competing” with substrate for binding in the 
active site of the enzyme. These molecules bind exclusively in the active site and the 
inhibition effect, they cause, can be reversed by increasing the substrate 
concentration. Classification of a potential inhibitor as competitive including its 




Figure E2: Determination of inhibition constant of a competitive inhibitor. The 
reaction rate is illustrated as v while the substrate and the inhibition constant of the 





Uncompetitive type of inhibition 
 
 
While a competitive inhibitor binds exclusively in the active site of a given enzyme, 
the uncompetitive one demands binding of substrate. As the model of figure E1 
shows, an uncompetitive inhibitor forms a complex with the enzyme while the 
substrate is already bound. This is a rare type of inhibition and it can be characterized 














Figure E3: Determination of inhibition constant and the type of inhibition of an 
uncompetitive inhibitor. The reaction rate, substrate and inhibition constant of the 




Non-competitive type of inhibition 
 
 
The inhibition graphs of the last and most interesting type of enzyme inhibition are 
illustrated in figure E4. While the inhibitor is not affected by binding of substrate, Ki 
(EI complex) and K´I (ESI complex) are equal. 
 
Figure E4: Determination of inhibition constant and the type of inhibition of a non-
competitive inhibitor. The reaction rate, substrate and inhibition constants of the 















































Figure F1: Illustration of (a) hTDO and (b) hIDO2 gel filtrations. hTDO is eluted in 
20mM TrisHCl buffer pH 8.0, 1mM TCEP using Superdex-200 (hTDO fraction = 
~150-200 ml);  hIDO2 is eluted in the same buffer using Superdex-75 (hIDO2 
fraction = ~140-160 ml). 
